使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings and welcome to the Align Technology First Quarter Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technology 第一季財報電話會議。(接線員指示)提醒各位,本次會議將被錄音。
It is now my pleasure to introduce your host, Shirley Stacy, VP of Corporate and Investor Communications. Thank you. You may begin.
現在我很榮幸介紹本次會議主持人:企業與投資人溝通副總裁 Shirley Stacy。謝謝。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you. Good afternoon, everyone. Thank you for joining us. Joining me today is Joe Hogan, President and CEO; and John Morici, CFO.
謝謝。各位下午好。感謝各位加入我們。今天與我一同出席的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。
We issued first quarter 2020 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. Telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on May 13. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13701221 followed by pound. International callers should dial (201) 612-7415 with the same conference number.
我們今天透過 GlobeNewswire 發布了 2020 年第一季財務結果,您可至我們的網站 investor.aligntech.com 查閱。今天的電話會議將以音訊網路直播,並會在我們網站上封存約 1 個月。電話重播預計將於今日美東時間下午 5:30 左右提供,並持續至 5 月 13 日美東時間下午 5:30。若要收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議號碼 13701221 後按井字鍵。國際來電者請撥打 (201) 612-7415,並使用相同的會議號碼。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results vary significantly, and Align expressly assumes no obligation to update any forward-looking statement.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件及產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近期向美國證券交易委員會(SEC)提交的定期報告中更詳細說明,該等文件可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We have posted historical financial statements, including the corresponding reconciliations, if applicable, and our first quarter 2020 conference and earnings release and conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
我們已在網站的「季度結果」專區發布歷史財務報表(如適用亦包含相應調節表),以及 2020 年第一季電話會議與財報新聞稿及電話會議簡報投影片。請參閱這些檔案以取得更詳細資訊。
With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon and thanks for joining us. I hope that you and your families are well. Given the significant disruption to our business caused by the extraordinary measures taken by governments, public and private institutions and businesses around the world to fight the spread of COVID-19, most of the performance metrics I would normally discuss are less meaningful. Therefore, on our call today, in addition to the highlights from our Q1 results, I'll discuss the trends that we're seeing through early March prior to the escalation in the COVID-19 cases that resulted in shutdowns across Europe and North America, and compounded the initial impact from similar shutdowns in China beginning in January. I'll also talk about our view of recovery and strategy to help our doctor customers navigate this challenging environment and ensure our business continuity. John will provide more detail on our financial performance and comment on the current trends across our business globally, including the momentum we're beginning to see in China. Following that, I'll come back and summarize a few key points and open up the call to questions.
謝謝,Shirley。各位下午好,感謝加入我們。希望各位與家人都平安。鑑於全球各國政府、公私立機構與企業為對抗 COVID-19 擴散而採取的非常措施,對我們業務造成重大干擾,我平常會討論的大多數績效指標如今意義不大。因此,在今天的電話會議中,除了第一季業績重點外,我也會談談我們在 3 月上旬、也就是 COVID-19 病例升高並導致歐洲與北美封鎖停擺之前所觀察到的趨勢;而這些停擺也加劇了中國自 1 月起類似停擺所帶來的初始影響。我也會談談我們對復甦的看法,以及協助醫師客戶在此艱困環境中因應並確保業務持續運作的策略。John 將更詳細說明我們的財務表現,並評論全球各地業務的當前趨勢,包括我們在中國開始看到的動能。之後我會回來總結幾個重點,並開放提問。
With that, let me start with a few comments on our first quarter results through early March. At that time, China was progressing in line with our original guidance for Q1, which included approximately 20,000 to 25,000 fewer cases and $30 million to $35 million less revenues for Invisalign and iTero products, and other regions were performing ahead of our Q1 outlook. However, the situation quickly changed in mid-March as most governments in EMEA and North America closed down nonessential businesses, initiated stay at home orders. As a result, the vast majority of Invisalign practices shut down and stopped seeing patients, and our business fell off sharply. We believe the incremental impact of COVID-19 on our Q1 results was approximately 50,000 fewer cases and approximately $85 million less revenues for Invisalign and iTero products.
接著,我先就 3 月上旬以前的第一季結果做幾點說明。當時,中國的進展符合我們原先對第一季的指引,其中包含 Invisalign 與 iTero 產品約少 20,000 至 25,000 例病例,以及營收約少 3,000 萬至 3,500 萬美元;而其他地區的表現則優於我們對第一季的展望。然而,情勢在 3 月中旬迅速改變,因為 EMEA 與北美多數政府關閉非必要商家並發布居家令。結果是,絕大多數 Invisalign 診所關閉並停止看診,我們的業務急遽下滑。我們認為,COVID-19 對第一季結果的額外影響約為少 50,000 例病例,以及 Invisalign 與 iTero 產品營收約少 8,500 萬美元。
At the same time, while EMEA, North America and other parts of APAC fell off in mid-March, we began to see improvements in China as the country started to open up again. While it's still early in the recovery process and the situation is different in every city and for every practice, we're working closely with our doctors to support their current needs and ensure they have a game plan to resume operations in a very different environment for the foreseeable future. More on that in a few minutes.
同時,當 EMEA、北美及 APAC 其他地區在 3 月中旬下滑之際,隨著中國開始重新開放,我們開始看到改善。雖然復甦仍在早期階段,且每個城市、每家診所的情況都不同,但我們正與醫師密切合作,支持他們當前的需求,並確保他們在可預見的未來、於截然不同的環境下,具備恢復營運的行動計畫。幾分鐘後我會再多談一些。
Now let's go through our first quarter results. For Q1, total revenues were $551 million, down 15.2% sequentially and unchanged year-over-year, reflecting significantly lower-than-expected sales of Invisalign clear aligners and iTero scanners due to the COVID-19 pandemic. Revenues from clear aligners were $481.6 million, and iTero scanners and services were $69.4 million. Clear aligner shipments were 359,400 cases. Notwithstanding the impact of COVID-19, shipment volumes were up 2.9% year-over-year, reflecting solid growth from noncomprehensive products driven by Invisalign Go systems across all regions as well as Invisalign Moderate. This was offset by a lower mix of comprehensive products primarily due to the shortfall in China.
現在我們來看第一季結果。第一季總營收為 5.51 億美元,較前一季下降 15.2%,與去年同期持平,反映因 COVID-19 疫情導致 Invisalign 隱形矯正器與 iTero 掃描儀銷售顯著低於預期。隱形矯正器營收為 4.816 億美元,iTero 掃描儀與服務營收為 6,940 萬美元。隱形矯正器出貨量為 359,400 例病例。儘管受到 COVID-19 影響,出貨量仍較去年同期成長 2.9%,反映由 Invisalign Go 系統在各地區帶動的非全療程產品穩健成長,以及 Invisalign Moderate 的成長;但由於中國短缺,導致全療程產品占比下降,抵銷了部分成長。
For the quarter, we shipped Invisalign cases to approximately 61,000 doctors, of which 4,100 were first time customers. We also trained over 4,600 new doctors in Q1, including 2,600 international doctors. Overall for the teen market in Q1, 104,000 teens and preteens started treatment with Invisalign clear aligners, representing 29% of total cases shipped, reflecting growth from EMEA and the Americas regions and across comprehensive products.
本季我們向約 61,000 位醫師出貨 Invisalign 病例,其中 4,100 位為首次客戶。我們在第一季也訓練了超過 4,600 位新醫師,其中包含 2,600 位國際醫師。整體而言,第一季青少年市場共有 104,000 名青少年與學齡前青少年開始使用 Invisalign 隱形矯正器治療,占總出貨病例的 29%,反映 EMEA 與美洲地區的成長,以及全療程產品的成長。
During the quarter, we reached another major milestone with our 2 millionth Invisalign teenage patient, Kaitlynn Ratliff. A student and athlete, we started treatment recently with Dr. Tom Hartsock, a U.S.-based orthodontist in Kentucky. Dr. Hartsock has been a terrific practicing orthodontic for about 30 years and credits Invisalign with revitalizing his practice at a time when a lot of doctors think about slowing down. He says his approach is to lead with Invisalign, and he's got a new digital mindset now, and we're excited he's going to share more about that at our upcoming Invisalign Teen Forum "Virtual Edition" this July. The teen segment represents the largest portion of existing orthodontic case starts each year. And as we head into the summer season, the busiest time in orthos practice, we are working to help doctors capture as much of the teen season as possible under the circumstances.
本季我們也達成另一個重要里程碑:第 200 萬位 Invisalign 青少年患者 Kaitlynn Ratliff。她是一名學生兼運動員,近期在美國肯塔基州的矯正專科醫師 Tom Hartsock 醫師處開始治療。Hartsock 醫師從事矯正臨床約 30 年,並認為 Invisalign 在許多醫師開始考慮放慢腳步之際,讓他的診所重獲活力。他表示他的做法是以 Invisalign 作為首選,現在也建立了新的數位思維;我們很期待他在今年 7 月即將舉行的 Invisalign Teen Forum「虛擬版」中分享更多。青少年族群每年占既有矯正病例啟動量的最大比重。隨著我們進入暑期——矯正診所最繁忙的季節——我們正努力在現有情況下協助醫師盡可能掌握青少年旺季需求。
Now let's turn to specifics around our first quarter results, starting with the Americas region. For the Americas region, through early March, solid sequential growth was driven primarily by North American GP dentists and DSOs, along with continued strength in Latin American doctors. On a reported basis, Q1 Invisalign case volume was down 5.5% sequentially and up 5.2% year-over-year, reflecting significantly less-than-expected Invisalign case shipments in March due to the impact of COVID-19. Year-over-year growth for Q1 reflects growth from both orthodontist and GP dentist channels, which were up 5.6% and 4.6%, respectively. Latin America volume was up 83% year-over-year led by strong growth from Brazil.
接下來我們談第一季結果的細節,先從美洲地區開始。美洲地區在 3 月上旬以前,穩健的季增成長主要由北美一般牙醫(GP)與牙科服務組織(DSO)帶動,並且拉丁美洲醫師需求持續強勁。以報告基礎計算,第一季 Invisalign 病例量較前一季下降 5.5%,較去年同期成長 5.2%,反映 3 月因 COVID-19 影響導致 Invisalign 病例出貨顯著低於預期。第一季的年增成長反映矯正專科與一般牙醫通路皆有成長,分別年增 5.6% 與 4.6%。拉丁美洲病例量較去年同期成長 83%,主要由巴西的強勁成長帶動。
For our international business, through early March, with the exception of China, the EMEA and APAC regions were performing well. On a reported basis, Q1 Invisalign case volume was down 22.3%, sequentially reflecting significant decrease in APAC, primarily China, due to the impact from COVID-19, partially offset by growth in EMEA. On a year-over-year basis, international shipments are flat, reflecting growth from EMEA, offset by a decline in APAC.
就我們的國際業務而言,除中國外,EMEA 與 APAC 地區在 3 月上旬以前表現良好。以報告基礎計算,第一季 Invisalign 病例量較前一季下降 22.3%,反映 APAC(主要是中國)因 COVID-19 影響而大幅下滑,部分由 EMEA 的成長所抵銷。以年增角度來看,國際出貨量持平,反映 EMEA 的成長被 APAC 的下滑所抵銷。
For EMEA, Q1 volumes were down sequentially and up 11.1% on a year-over-year basis driven by growth in Spain, the U.K. and Germany, along with our expansion markets led by Central Eastern Europe and Benelux, including the teen segment.
就 EMEA 而言,第一季出貨量較前一季下滑,但在西班牙、英國與德國成長,以及以中東歐與比荷盧為首的擴張市場(包含青少年族群)帶動下,年增 11.1%。
For APAC, Q1 was down sequentially as expected, reflecting a significant reduction in volume in China due to COVID-19. On a year-over-year basis, APAC was down 18.2% compared to the prior year, reflecting a longer duration of COVID-19 measures implemented in China and was the only region down year-over-year. Japan, Taiwan, Korea and India saw continued year-over-year growth in Q1. And as noted earlier, we began to see signs of improvement in China in early March as the government began to relax some or all of the restrictions and business began the road to recovery.
就 APAC 而言,第一季如預期較前一季下滑,反映中國因 COVID-19 導致出貨量大幅減少。以年對年來看,APAC 較去年同期下滑 18.2%,反映中國實施 COVID-19 措施的期間較長,且為唯一年對年下滑的區域。日本、台灣、韓國與印度在第一季仍持續呈現年對年成長。如先前所述,隨著政府於 3 月初開始放寬部分或全部限制、商業活動踏上復甦之路,我們也開始在中國看到改善跡象。
Our consumer marketing is focused on building the clear aligner category and driving demand for Invisalign treatment through a doctor's office. In Q1, we saw strong digital engagement globally, including 7.1 million unique visitors to our websites and 274,000 leads, both metrics growing by more than 40%. Consumer engagement growth for Invisalign was enabled by the launch of our new consumer campaign, Invis is, strong media spend and a robust omnichannel presence. Our Invisalign concierge team is nurturing consumer leads and virtually until doctors' offices open, which is key to realizing and converting consumer interest into cases. Further, our modeling indicates that consumer marketing drove incremental growth in Q1 and reinforces our strategy to invest in brand building and maintain high visibility with consumers through the COVID-19 crisis. Other key metrics show increased activity and engagement with the Invisalign brand and are included in our Q1 quarterly slides.
我們的消費者行銷聚焦於建立透明矯正器(clear aligner)品類,並透過醫師診所推動 Invisalign 治療需求。第一季,我們在全球看到強勁的數位互動表現,包括網站 710 萬名不重複訪客與 27.4 萬筆潛在客戶名單(leads),兩項指標皆成長超過 40%。Invisalign 的消費者互動成長,得益於我們推出全新消費者活動「Invis is」、強勁的媒體投放,以及穩健的全通路(omnichannel)佈局。我們的 Invisalign concierge 團隊在醫師診所重新開放前,持續培育消費者名單並以線上方式互動,這對於將消費者興趣落實並轉化為病例(cases)至關重要。此外,我們的模型顯示,消費者行銷在第一季帶來增量成長,並強化我們在 COVID-19 危機期間持續投入品牌建設、維持高消費者能見度的策略。其他關鍵指標亦顯示 Invisalign 品牌活動與互動提升,並已納入我們第一季季度簡報投影片中。
For iTero scanner and services business, Q1 revenues were down sequentially as expected, following a seasonally strong Q4 and consistent with trends in the capital equipment market. Q1 also reflects the impact of COVID-19 across all regions and especially North America, Australia, China, Japan and other APAC countries. On a year-over-year basis, iTero scanner revenues were down 13.1% due to lower sales in North America and APAC region primarily due to COVID-19 despite increased revenues in EMEA and Latin America, reflecting the addition of Zimmer Biomet distribution agreement, the introduction of our iTero 5D, going direct to Mexico and additional LATAM distributor markets. The total year-over-year decrease in scanner revenue was slightly offset by increased services revenue from a larger iTero installed base.
就 iTero 掃描儀與服務業務而言,第一季營收如預期較前一季下滑,係因第四季季節性表現強勁,且與資本設備市場趨勢一致。第一季亦反映 COVID-19 對所有地區的影響,尤其是北美、澳洲、中國、日本及其他 APAC 國家。以年對年來看,iTero 掃描儀營收下滑 13.1%,主要因北美與 APAC 地區銷售下降(主要受 COVID-19 影響),儘管 EMEA 與拉丁美洲營收增加;該增長反映新增 Zimmer Biomet 經銷協議、推出 iTero 5D、在墨西哥採取直營模式,以及新增其他拉美經銷市場。掃描儀營收年對年總降幅,部分被 iTero 裝機量(installed base)擴大所帶動的服務營收成長所抵銷。
Cumulatively, over 23 million orthodontic scans, 5.2 million restorative scans have been performed with iTero scanners. For Q1, total Invisalign cases submitted with a digital scanner in the Americas increased to 80.5% from 76.1% in Q1 last year. International scans increased 68.7%, up from 59.3% in the same quarter last year. We're pleased to see that within the Americas, 93.6% of cases submitted by North American orthodontists were submitted digitally.
累計而言,使用 iTero 掃描儀已完成超過 2,300 萬次齒顎矯正掃描與 520 萬次修復(restorative)掃描。第一季,美洲地區以數位掃描儀提交的 Invisalign 病例占比提升至 80.5%,高於去年第一季的 76.1%。國際市場的數位掃描占比提升至 68.7%,高於去年同季的 59.3%。我們也很高興看到,在美洲地區,北美矯正醫師提交的病例中有 93.6% 以數位方式提交。
I'm also pleased to share that we received FDA 510(k) clearance for our iTero Element 5D Imaging System. The iTero Element 5D Imaging System seamlessly combines 3 scanning technologies, 3D data, intra-oral color photos and NIRI images. NIRI is near-infrared imaging technology, which allows you to see caries in different aspects from a dentition standpoint. It's an integrated scan, and we're excited to bring the advancement in intra-oral scan technology to the United States market to help doctors provide better oral care for their patients.
我也很高興分享,我們的 iTero Element 5D 影像系統已取得 FDA 510(k) 核准(clearance)。iTero Element 5D 影像系統可無縫整合 3 種掃描技術、3D 資料、口內彩色照片與 NIRI 影像。NIRI 為近紅外線影像技術(near-infrared imaging technology),可從牙列(dentition)的角度在不同面向觀察齲齒(caries)。這是一套整合式掃描系統,我們很期待將口內掃描技術的進步帶入美國市場,協助醫師為患者提供更好的口腔照護。
At this time, we're mindful of the current environment and the impact that COVID-19 pandemic is having across the world and are focused on customer education and training regarding this new technology while so many dental practices in the U.S. are operating on a limited schedule.
在此時此刻,我們留意當前環境以及 COVID-19 疫情對全球造成的影響;在美國許多牙科診所仍以有限時段營運之際,我們將重點放在針對此新技術的客戶教育與訓練。
We remain confident that the iTero business will continue to help drive our overall long-term growth and help increase adoption of the digital platform with Invisalign treatment. To that end, during the quarter, we announced the acquisition of exocad, a global CAD/CAM software leader, and completed the transaction on April 1. John will talk more about the acquisition in a moment, but let me say just that the rise in consumer awareness around dentistry extends beyond the benefits of straight teeth and orthodontics. There are significant opportunities for all kinds of treatments, from simple cosmetic fixes to ortho-restorative. That can help us accelerate growth of our digital solutions for ortho-restorative cases and really drive growth and adoption of the Invisalign iTero digital platform. I'm very excited about the addition of exocad's proven restorative experience, expertise and functionality to our platform, and I want to welcome exocad Founders, Till Steinbrecher and Maik Gerth and the entire exocad team to Align.
我們仍有信心 iTero 業務將持續推動我們整體的長期成長,並協助提升 Invisalign 治療的數位平台採用率。為此,我們在本季宣布收購全球 CAD/CAM 軟體領導者 exocad,並於 4 月 1 日完成交易。John 稍後會進一步說明這項收購;但我想先指出,消費者對牙科的認知提升,已不僅止於牙齒整齊與齒顎矯正的益處。從簡單的美觀修復到矯正-修復(ortho-restorative)等各類治療,都存在重大機會。這將有助於我們加速矯正-修復病例的數位解決方案成長,並真正推動 Invisalign iTero 數位平台的成長與採用。我對於將 exocad 經驗證的修復領域經驗、專業能力與功能加入我們的平台感到非常振奮,也在此歡迎 exocad 創辦人 Till Steinbrecher 與 Maik Gerth,以及整個 exocad 團隊加入 Align。
Let me now turn to some of the initiatives we've taken to support our doctors and their patients.
接下來我想談談我們為支持醫師及其患者所採取的一些措施。
We recognize the enormous hardship that COVID-19 has caused Invisalign practices around the world. We're working every region to support doctors and find ways to minimize disruptions to their businesses and to strengthen the experiences their patients have with Invisalign treatment. We have learned a lot from our doctor partners and teams in the Asia Pacific region, and we've been navigating the impact of COVID-19 for months. We're applying their experiences and insights across all regions. Many of our customers are sharing creative ideas and suggestions as we all work to manage the situation together.
我們了解 COVID-19 對全球 Invisalign 診所造成了巨大的困境。我們在各個地區努力支援醫師,並尋找方法將其業務中斷降至最低,同時強化患者接受 Invisalign 治療的體驗。我們從亞太地區的醫師合作夥伴與團隊身上學到很多,也已數月來持續因應 COVID-19 的影響。我們正將他們的經驗與洞見應用到所有地區。許多客戶也在分享創意想法與建議,讓我們能共同管理這個局勢。
One of the first things we did was address clinical education, an integral part of doctor engagement. Across all 3 of our regions, we moved most of our education programs to online digital platforms, continuing to provide hundreds of valuable Invisalign and iTero training and education resources, many peer-to-peer for doctors and their teams, in a virtual setting. We also identified opportunities to collaborate with Invisalign practices to manage ongoing cases and explore new ways for doctors to conduct consultations. Early on, many doctors began using video calls, text and patient-submitted photos through a variety of platforms to help monitor patient progress, reduce in-office appointments and ensure continuity of patient care during treatment. It quickly became clear that doctors needed a better way to connect and monitor patients. So we accelerated the launch of new tools that were still in pilot mode. The Invisalign virtual appointment tool enables doctors to easily set up HIPAA-compliant video appointments to monitor existing patients and to have an initial conversation with patients interested in learning more about Invisalign clear aligner treatment with a doctor. The Invisalign virtual care program can also use video appointments and enables doctors to monitor treatment progress and stay connected with patients through a virtual platform. Patients use the intuitive My Invisalign app to stay engaged in the treatment and convey progress photos to their doctor who review these photos on their Invisalign doctor site, communicates any needed instruction and ensures treatment is on track. These tools are available through our Invisalign Doctor Site, IDS, in the My Invisalign app, and work as part of the end-to-end digital platform for Invisalign treatment. While both tools are still in early stages of rollout, our goal is to provide doctors with a way to maintain care until patients are again able to visit the doctor's office. Feedback to date has been relatively positive, and we believe that doctors will continue using these tools to improve patient experience and increase office efficiencies well after COVID-19 restrictions have been listed.
我們最早採取的措施之一,是處理臨床教育——這是醫師互動的重要一環。在我們 3 個地區中,我們將大多數教育計畫移轉至線上數位平台,持續以虛擬方式提供數百項有價值的 Invisalign 與 iTero 訓練與教育資源,其中許多為醫師及其團隊的同儕交流(peer-to-peer)內容。我們也找出與 Invisalign 診所合作的機會,以管理進行中的病例並探索醫師進行諮詢的新方式。早期,許多醫師開始透過多種平台使用視訊通話、簡訊與患者自行提交的照片,以協助監測患者進度、減少到院次數,並在治療期間確保照護的連續性。很快就清楚顯示,醫師需要更好的方式來連結並監測患者。因此,我們加速推出仍處於試點(pilot)階段的新工具。Invisalign 虛擬約診工具可讓醫師輕鬆建立符合 HIPAA 規範的視訊約診,用於監測既有患者,並與有興趣進一步了解 Invisalign 透明矯正器治療的患者進行初步對談。Invisalign 虛擬照護計畫同樣可使用視訊約診,並使醫師能透過虛擬平台監測治療進度並與患者保持連結。患者使用直覺易用的 My Invisalign 應用程式維持治療參與度,並將進度照片傳送給醫師;醫師則在其 Invisalign 醫師網站上檢視照片、提供必要指示並確保治療按計畫進行。這些工具可透過我們的 Invisalign Doctor Site(IDS)與 My Invisalign 應用程式取得,並作為 Invisalign 治療端到端數位平台的一部分運作。雖然兩項工具仍處於早期推廣階段,我們的目標是為醫師提供一種方式,在患者能再次回到診所前維持照護。迄今收到的回饋相對正面,我們相信即使在 COVID-19 限制解除後,醫師仍會持續使用這些工具,以改善患者體驗並提升診所效率。
We're also supporting doctors through financial and operating challenges and are providing additional resources, including industry experts to help them navigate this ongoing crisis. This includes webcast, e-blast and micro sites on IDS again, the Invisalign Doctor Site, with advice on extending aligner wear and holding patients at specific treatment stages. Options for redirecting aligner shipments and helping address customer cash flow concerns caused by the pandemic. We're creating programs with partners like LendingPoint that are part of recovery playbooks to help doctors with speed to cash that is expected to launch in May -- on May 1.
我們也正透過財務與營運層面的支援來協助醫師,並提供額外資源,包括產業專家,協助他們因應這場持續的危機。這包括在 IDS(Invisalign Doctor Site,隱適美醫師網站)上再次推出的網路直播(webcast)、電子快訊(e-blast)與微型網站(micro sites),提供關於延長牙套配戴時間以及讓患者停留在特定治療階段的建議。也提供重新導向牙套出貨的選項,並協助處理因疫情造成的客戶現金流疑慮。我們正與 LendingPoint 等合作夥伴共同建立計畫,作為復甦作戰手冊的一部分,協助醫師加速回收現金,預計於 5 月推出——5 月 1 日。
Before I turn the call over to John, I'd like to spend a few minutes talking about the strength and resiliency of Align and our business model and our view of the path to recovery. There's no question that we are in uncharted territory. And while supporting our doctors in their current situation is still critical right now, planning for recovery is just as important. Overcoming challenges is not new to Align and our employees. Our response to COVID-19 and decisions and investments we are making now to anticipate customer needs and adapt in a dynamic environment are based in part on the lessons learned throughout our history and will further our competitive advantage and position us to capitalize on the market as it returns. We serve a huge underpenetrated market, and our share of more than 300 million people who want a better smile is less than 3%. Teens are an important segment, and our share is a small fraction of the market. And yet, we know that teens remain the heart and soul of orthodontic practices and will drive their recovery. There is no single blueprint for us to follow in this recovery. Our underlying business is healthy. We have an excellent balance sheet with no debt. And over the last 5 years, we've grown a business that has generated 25% compounded revenue growth and consistently delivered 72% gross margins, 22% operating margins and generated cash flow from operations in excess of 22% of revenues each year. We also have operational resiliency in terms of global manufacturing that has taken us years to develop and is simply unmatched, and is a key reason why we're able to continue operations in the crisis and expect to ramp up quickly in recovery. The core components being supply chain, digital treatment planning, treat, aligner fabrication AFAB, supply chain. During normal business, we carry enough buffer stock in our warehouse to handle 2 disruptions to the supply chain. So if a batch goes sideways, we can handle that twice. After COVID-19 broke in China, we anticipated that we needed to mobilize existing suppliers and add 3 to 6 months of additional inventory so that we could weather the potential storm. For many of our suppliers, we have alternative redundant suppliers in case a shutdown in one geography impacts a supplier. TREAT. The investments we have made over the years in having TREAT in multiple locations, allows us some flexibility in business continuity to respond to customer needs. Before COVID-19, we had evaluated potential for doing treatment planning from home or remote locations and the implications to hardware needs, data security and productivity. When COVID-19 hit China, we ramped up our ability to do that and started transitioning our CAD designers to do treatment planning at home and have been successful in that sense. We are confident we could have maintained 80% of our normal output, but volumes fell off before we could prove that point. China hit first, so we load balanced with our other TREAT locations. So as this went from east to west, we didn't have significant issues in our treatment operations. This is our model, and we'll continue to strengthen it going forward.
在我把電話交給 John 之前,我想花幾分鐘談談 Align 及其商業模式的強健與韌性,以及我們對復甦路徑的看法。毫無疑問,我們正處於未知領域。雖然在當下持續支援醫師面對現況仍然至關重要,但為復甦做規劃同樣重要。克服挑戰對 Align 與我們的員工而言並不陌生。我們對 COVID-19 的回應,以及我們現在為了預先掌握客戶需求並在動態環境中調整而做出的決策與投資,部分是基於我們歷史上累積的經驗教訓,並將進一步強化我們的競爭優勢,使我們在市場回溫時能把握機會。我們服務的是一個滲透率極低的龐大市場;在超過 3 億名想要更美笑容的人口中,我們的市占率不到 3%。青少年是重要的細分市場,而我們的占比也只是市場中的一小部分。然而,我們知道青少年仍是矯正診所的核心與靈魂,並將帶動其復甦。這次復甦沒有單一可遵循的藍圖。我們的基本面健康。我們擁有優異的資產負債表且沒有負債。過去 5 年,我們打造出一個營收複合成長率達 25% 的業務,並持續維持 72% 的毛利率、22% 的營業利益率,且每年營運現金流均超過營收的 22%。我們也具備營運韌性,體現在多年打造、無可匹敵的全球製造能力;這也是我們能在危機中持續營運並預期在復甦時快速提升產能的關鍵原因。其核心組成包括供應鏈、數位治療規劃、TREAT、牙套製造(AFAB)、供應鏈。在正常營運下,我們在倉庫中保有足夠的緩衝庫存,可應對供應鏈的 2 次中斷。因此如果某一批次出狀況,我們可以承受兩次。COVID-19 在中國爆發後,我們預期需要動員既有供應商並增加 3 到 6 個月的額外庫存,以便度過可能的風暴。對於許多供應商,我們也有替代性的備援供應商,以防某一地區的停工影響供應。TREAT:多年來我們在多個地點部署 TREAT 的投資,使我們在營運持續性上更具彈性,以回應客戶需求。在 COVID-19 之前,我們已評估在家或遠端進行治療規劃的可行性,以及對硬體需求、資料安全與生產力的影響。當 COVID-19 影響中國時,我們提升了這方面的能力,並開始讓 CAD 設計師在家進行治療規劃,且在這方面取得成功。我們有信心原本可以維持正常產出的 80%,但在我們能證明這點之前,需求量就已下滑。中國最先受到衝擊,因此我們透過其他 TREAT 據點進行負載平衡。當疫情由東向西擴散時,我們的治療作業並未出現重大問題。這就是我們的模式,未來我們也會持續強化。
Aligner fabrication. We have aligner fabrication operations in Ziyang, China and Juarez, Mexico and plans for a third facility in Europe that we're looking to accelerate into 2021. Our facilities have excess capacity built in. And while we never have 100% redundancy, we do have the ability to shift production volumes based on that excess capacity. Worst case scenario, if one of these facilities goes down, then customers wait a little longer for their aligners, but production will continue, and we believe we can recover swiftly.
牙套製造:我們在中國資陽與墨西哥華雷斯設有牙套製造營運據點,並規劃在歐洲設立第三座工廠,我們正考慮加速於 2021 年完成。我們的工廠內建有超額產能。雖然我們從未達到 100% 的備援冗餘,但我們確實能依據這些超額產能來調整與轉移生產量。最壞情況下,若其中一座工廠停擺,客戶可能需要多等一段時間才能收到牙套,但生產仍會持續,我們相信能迅速恢復。
In short, when we have an issue in one part of the world, we have designed our operations to enable us to load balance across facilities. We've had to do this because of our growth and huge growth spurts that made it necessary to remain flexible. Additionally, the steps we've implemented during COVID crisis, like work-from-home for CAD designers gives us even more flexibility, and we'll leverage that going forward as we evaluate facilities requirements and potential cost savings.
簡而言之,當世界某個地區出現問題時,我們的營運設計使我們能在各工廠之間進行負載平衡。我們之所以必須這麼做,是因為我們的成長以及多次快速成長的高峰,使得保持彈性變得必要。此外,我們在 COVID 危機期間實施的措施,例如讓 CAD 設計師在家工作,讓我們擁有更高的彈性;在我們評估廠房需求與潛在成本節省時,也會在未來持續加以運用。
Beyond our business strength and operational resiliency, we are at the forefront of digital dentistry. And this pandemic has exposed the weakness of analog approaches and strengthens and benefits the digital technology in every aspect of our life. There's been a lot of concern over the years about digital driving us apart and keeping people from interacting. People focused on their screens in social media rather than with each other, interacting with businesses online rather than in person, et cetera. I think what we're seeing through this terrible situation is that digital actually unites us. It keeps us connected, gives us flexibility and options. Without digital technology during this crisis, how would kids go to school? How would any of us be productive working from home? How would universities and public health experts model the curve without data mining and AI? I am proud and thankful of our digital platform is able to Invisalign patients moving forward in treatment while physical practices are closed, that it can connect doctors and patients to monitor issues and track treatment, that because of digital, we can get a replacement aligner for some new -- or some new retainers to a kid sheltering in place. Together with doctors, we're going to leverage that power of digital for dentistry and orthodontics more than ever. Doctors are not going back to before. We all know that digital dentistry is the future, and that is a part of why Align is weathering this pandemic and why I believe we are well positioned for success going into recovery.
除了我們的業務實力與營運韌性之外,我們也站在數位牙科的最前線。這場疫情暴露了類比作法的弱點,並在我們生活的各個層面強化並凸顯數位科技的價值。多年來,人們一直擔心數位化會讓我們彼此疏離、減少互動:人們在社群媒體上盯著螢幕而不是彼此交流、與企業在線上互動而非面對面,等等。我認為我們在這個艱難情況中看到的是:數位其實讓我們更團結。它讓我們保持連結,提供彈性與選擇。若在這次危機中沒有數位科技,孩子要如何上學?我們任何人要如何在家工作仍保持生產力?大學與公共衛生專家要如何在沒有資料探勘與 AI 的情況下建模疫情曲線?我為我們的數位平台感到自豪並心懷感謝:即使實體診所關閉,它仍能讓 Invisalign 患者持續推進治療;它能連結醫師與患者以監測問題並追蹤治療;也因為數位化,我們能把替換牙套——或新的維持器——送到正在就地避難的孩子手中。我們將與醫師一起,比以往更充分地運用數位在牙科與齒顎矯正領域的力量。醫師不會回到從前。我們都知道數位牙科是未來,而這也是 Align 能挺過這場疫情、並且我相信我們在走向復甦時具備成功優勢的原因之一。
With that, I'll now turn it over to John.
接下來,我把時間交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q1 financial results. Total revenue for the first quarter was $551 million, down 15.2% from the prior quarter and up 0.4% from the corresponding quarter a year ago. For clear aligners, Q1 revenues of $481.6 million was down 11.4% sequentially across all regions driven by Asia Pacific. Year-over-year clear aligner revenues growth of 2.6% reflects growth from EMEA and the Americas, offset by APAC. Clear aligner revenue growth was unfavorably impacted by approximately $6 million or approximately 1 point year-over-year from foreign exchange.
謝謝你,Joe。接著說明我們第一季的財務結果。第一季總營收為 5.51 億美元,較前一季下降 15.2%,較去年同期增加 0.4%。就透明牙套而言,第一季營收為 4.816 億美元,受亞太地區帶動影響,所有地區的營收較前一季下降 11.4%。透明牙套營收年增 2.6%,反映 EMEA 與美洲地區的成長,並被 APAC 的下滑所抵銷。透明牙套營收成長亦受到外匯影響而不利,年對年約減少 600 萬美元,或約 1 個百分點。
Q1 Invisalign ASPs were up sequentially by approximately $15 to $1,255, primarily due to lower net deferrals due to a decrease in primary case shipments across all regions. On a year-over-year basis, Q1 Invisalign ASPs increased approximately $10, primarily reflecting price increases in all regions and increased additional aligner revenues, partially offset by promotional discounts and unfavorable foreign exchange.
第一季 Invisalign ASP(平均銷售價格)較前一季上升約 15 美元至 1,255 美元,主要因所有地區的主要病例出貨量下降,導致淨遞延金額較低。以年對年來看,第一季 Invisalign ASP 約增加 10 美元,主要反映所有地區的價格上調以及額外牙套營收增加,部分被促銷折扣與不利的外匯因素所抵銷。
Total Q1 Invisalign shipments of 359,400 cases, were down 13.1% sequentially and up 2.9% year-over-year. Our scanner and services revenue for the first quarter was $69.4 million, down 34.7% sequentially due to volume decreases in all regions. Year-over-year revenues were down 13.1%, primarily due to volume decreases in North America, partially offset by increases in EMEA and LATAM, and increases in service revenue off an increased installed base.
第一季 Invisalign 總出貨量為 359,400 例,較前一季下降 13.1%,較去年同期增加 2.9%。第一季我們的掃描儀與服務營收為 6,940 萬美元,因所有地區的出貨量下滑,較前一季下降 34.7%。年對年營收下降 13.1%,主要因北美出貨量下降,部分被 EMEA 與 LATAM 的增加,以及因裝機基數擴大而帶動的服務營收增加所抵銷。
Moving on to gross margin. First quarter overall gross margin was 71.6%, down 1 point sequentially and down 1.6 points year-over-year. On a non-GAAP basis, excluding stock-based compensation expense, overall gross margin was 71.8% for the first quarter, down 1 point sequentially and down 1.6 points year-over-year. Clear aligner gross margin for the first quarter was 73%, down 1.1 points sequentially and down 1.9 points year-over-year, primarily due to lower volumes and higher cost per case, partially offset by an increase in Invisalign ASPs.
接下來談毛利率。第一季整體毛利率為 71.6%,較前一季下降 1 個百分點,較去年同期下降 1.6 個百分點。以非 GAAP 基礎(排除以股票為基礎之薪酬費用)計算,第一季整體毛利率為 71.8%,較前一季下降 1 個百分點,較去年同期下降 1.6 個百分點。第一季透明矯正器毛利率為 73%,較前一季下降 1.1 個百分點,較去年同期下降 1.9 個百分點,主要因出貨量較低及每案例成本較高,部分由 Invisalign 平均售價(ASP)上升所抵銷。
Scanner gross margin for the first quarter was 61.8%, down 3.1 points sequentially and 1.8 points year-over-year due to increased manufacturing variances, lowering ASPs and partially offset by higher service revenue.
第一季掃描器毛利率為 61.8%,較前一季下降 3.1 個百分點、較去年同期下降 1.8 個百分點,原因為製造差異增加、ASP 下降,並部分由較高的服務營收所抵銷。
Q1 operating expenses were $324.4 million, up sequentially 1.1% and up 3.2% year-over-year. The sequential increase in operating expenses reflects higher legal and outside services. Year-over-year, the increase reflects our continued investment in sales and R&D activities, including increased compensation from additional headcount and consumer marketing spend, partially offset by the $29.8 million charge related to the Invisalign store closure costs recorded in Q1 of 2019.
第一季營業費用為 3.244 億美元,較前一季增加 1.1%,較去年同期增加 3.2%。營業費用的季增主要反映法律費用及外部服務費用較高。年增方面,則反映我們持續投資於銷售與研發活動,包括因新增人力而增加的薪酬以及消費者行銷支出;部分被 2019 年第一季認列之與 Invisalign 門市關閉成本相關的 2,980 萬美元費用所抵銷。
Our first quarter operating income was $69.9 million, down 53.7% sequentially and down 20.3% year-over-year. Our first quarter operating margin was 12.7%, down 10.6 points sequentially and down 3.3 points year-over-year. The sequential decrease in operating income and operating margin are primarily attributed to lower volume, revenue and gross margin as a result of the COVID-19 impacts.
第一季營業利益為 6,990 萬美元,較前一季下降 53.7%,較去年同期下降 20.3%。第一季營業利益率為 12.7%,較前一季下降 10.6 個百分點,較去年同期下降 3.3 個百分點。營業利益與營業利益率的季減主要歸因於 COVID-19 影響導致的出貨量、營收與毛利率下降。
Operating margin was impacted by approximately 0.8 points year-over-year from foreign exchange. On a year-over-year basis, the decrease in operating margin primarily reflects lower gross profit and higher operating expenses related to go-to-market activities, partially offset by the $29.8 million charge related to the Invisalign store closure in Q1 2019.
營業利益率較去年同期約受到外匯影響 0.8 個百分點。以年對年來看,營業利益率下降主要反映毛利較低以及與市場推廣(go-to-market)活動相關的營業費用較高;部分由 2019 年第一季與 Invisalign 門市關閉相關的 2,980 萬美元費用所抵銷。
On a non-GAAP basis, which excludes stock-based compensation, acquisition-related costs and impairment and other costs related to Invisalign store closures in the prior year, operating margin for the first quarter was 17.1%, down 9.3 points sequentially and down 8.1 points year-over-year.
以非 GAAP 基礎(排除以股票為基礎之薪酬、併購相關成本,以及前一年與 Invisalign 門市關閉相關的減損及其他成本)計算,第一季營業利益率為 17.1%,較前一季下降 9.3 個百分點,較去年同期下降 8.1 個百分點。
Interest and other income expense net for the first quarter was an expense of $16.9 million, including a $9.2 million hedge loss related to the anticipated exocad acquisition. Excluding the hedge loss, interest and other income expense net was $7.4 million expense on a non-GAAP basis.
第一季利息及其他損益淨額為費用 1,690 萬美元,其中包含與預期收購 exocad 相關的 920 萬美元避險損失。排除該避險損失後,以非 GAAP 基礎計算,利息及其他損益淨額為費用 740 萬美元。
With regards to the first quarter tax provision, our tax rate was negative 2,745%, which includes a onetime tax benefit of approximately $1.5 billion associated with the recognition of a deferred tax asset related to the intra entity sale of certain intellectual property rights resulting from our corporate structure reorganization completed during the quarter. This deferred tax benefit will be amortized starting in 2020 and continue into subsequent quarters and years. The period over which the tax benefit will be recognized depends on the profitability of our Swiss headquarters and is still under assessment and review with the Swiss tax authorities. Excluding the tax benefit related to our corporate structure reorganization and the related tax effects on stock-based compensation and other non-GAAP adjustments, the first quarter tax rate on a non-GAAP basis was 33.2% compared to 29 -- 20.9% in prior quarter and 22.8% in the same quarter a year ago. The non-GAAP tax rate was higher-than-forecasted due to lower-than-expected profits in regions outside the U.S.
關於第一季所得稅費用,我們的有效稅率為負 2,745%,其中包含約 15 億美元的一次性稅務利益,係與本季完成之公司架構重整所致、因企業內部出售特定智慧財產權而認列之遞延所得稅資產相關。此遞延稅務利益將自 2020 年起開始攤銷,並延續至後續季度與年度。稅務利益認列的期間取決於我們瑞士總部的獲利能力,目前仍在評估中,並與瑞士稅務機關進行審查。排除與公司架構重整相關的稅務利益,以及以股票為基礎之薪酬與其他非 GAAP 調整項目的相關稅務影響後,以非 GAAP 基礎計算,第一季有效稅率為 33.2%,相較前一季 20.9% 以及去年同期 22.8%。非 GAAP 稅率高於預期,係因美國以外地區的獲利低於預期。
First quarter diluted earnings per share was $19.21, up $17.68 sequentially and up $18.32 compared to the prior year. On a non-GAAP basis, diluted earnings per share was $0.73 for the first quarter, down $1.03 sequentially and down $0.52 year-over-year.
第一季稀釋每股盈餘為 19.21 美元,較前一季增加 17.68 美元,較去年同期增加 18.32 美元。以非 GAAP 基礎計算,第一季稀釋每股盈餘為 0.73 美元,較前一季減少 1.03 美元,較去年同期減少 0.52 美元。
Moving on to the balance sheet. As of March 31, 2020, cash, cash equivalents and marketable securities were $790.7 million, a decrease of approximately $77.9 million from the prior quarter, which is primarily due to the annual bonus payout and the purchase of an additional San Jose, California facility combined with slower AR collections. Of our $790.7 million of cash and cash equivalents, $119.2 million was held in the U.S. and $671.5 million was held by our international entities. Q1 accounts receivable balance was $533 million, down approximately 3.1% sequentially. Our overall days sales outstanding, DSOs, was 87 days, up 11 days sequentially and up 9 days as compared to Q1 last year. We expect DSOs to increase in Q2 as a result of anticipated lower collections.
接下來談資產負債表。截至 2020 年 3 月 31 日,現金、約當現金及有價證券為 7.907 億美元,較前一季減少約 7,790 萬美元,主要因年度獎金發放、購置加州聖荷西的另一處設施,以及應收帳款(AR)回收較慢所致。在 7.907 億美元的現金及約當現金中,1.192 億美元持有於美國,6.715 億美元由海外子公司持有。第一季應收帳款餘額為 5.33 億美元,較前一季約下降 3.1%。整體應收帳款週轉天數(DSO)為 87 天,較前一季增加 11 天,較去年第一季增加 9 天。我們預期第二季 DSO 將因預期回收較低而上升。
Cash flow from operations for the first quarter was $9.8 million. Capital expenditures for the first quarter were $46.1 million, primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow, defined as cash flow from operations less capital expenditures, amounted to negative $36.3 million. Under our May 2018 repurchase program, we still have $100 million available for repurchase of our common stock.
第一季營運活動現金流量為 980 萬美元。第一季資本支出為 4,610 萬美元,主要與我們持續投資以提升矯正器產能及設施相關。自由現金流量(定義為營運活動現金流量減資本支出)為負 3,630 萬美元。依據我們 2018 年 5 月的庫藏股回購計畫,目前仍有 1 億美元可用於回購普通股。
On April 1, 2020, we completed the acquisition of privately held exocad global whole needs, GMBH, a global leader in the dental CAD/CAM software market for a purchase price of approximately $430 million in cash. The acquisition of exocad broadens our digital platform reach by adding technology that addresses restorative needs in an end-to-end digital platform workflow to facilitate ortho restorative and comprehensive dentistry and also brings exocad's expertise in restorative dentistry, implantology, guided surgery and smile design of the Align Technology portfolio. We expect to complement and extend our Invisalign and iTero digital solutions, paving the way for new seamless, cross-disciplinary dentistry in the lab and at chair side. exocad also broadened our platform reach into digital dentistry with close to 200 partners and more than 35,000 licenses installed worldwide.
2020 年 4 月 1 日,我們完成收購私人持有的 exocad global whole needs, GMBH(exocad),其為牙科 CAD/CAM 軟體市場的全球領導者,收購價約為 4.30 億美元現金。收購 exocad 透過加入可在端到端數位平台工作流程中滿足修復需求的技術,擴大我們數位平台的觸及範圍,以促進齒顎矯正與修復以及全方位牙科;同時也將 exocad 在修復牙科、植牙學、導引手術與微笑設計方面的專業納入 Align Technology 的產品組合。我們預期可補強並延伸 Invisalign 與 iTero 的數位解決方案,為實驗室與診間端的新型無縫跨領域牙科鋪路。exocad 亦透過近 200 家合作夥伴及全球安裝超過 35,000 套授權,擴大我們在數位牙科領域的平台觸及。
Now let me turn to our outlook. As Joe described earlier, through early March, our business was performing well, and we believe we would exceed our Q1 guidance. However, things quickly changed in the latter part of March as the majority of Invisalign practices in our core markets in EMEA and the Americas regions closed their offices and stopped seeing patients, which caused Invisalign case receipts to drop rapidly and continue into April.
現在談談我們的展望。如同 Joe 先前所述,截至 3 月上旬,我們的業務表現良好,我們相信原本會超越第一季指引。然而,3 月下旬情勢迅速改變,因我們核心市場(EMEA 與美洲地區)多數 Invisalign 診所關閉並停止看診,導致 Invisalign 病例收件量快速下滑,並延續至 4 月。
At this time, due to the fluid market condition caused by the COVID-19 pandemic, we are not providing guidance for Q2, and we are withdrawing our prior commentary regarding our full year 2020. What I can offer is the following directional commentary: For China, which was the first major country impacted by COVID-19 and was shut down almost overnight at the end of January, as reflected in our Q1 guidance provided on the January earnings call, it has shown continued improvement beginning in early March. Our case receipts or orders in China are currently running at 80-plus percent of mid-January's level, but with fair amount of variability week-to-week in between various provinces and cities. Keep in mind that there is about a 3- to 4-week lag between case receipts and orders to case shipments. China provinces are not uniform in their recovery, but all continue to improve. Guangdong, Shanghai and Ziyang are now at or above prepandemic levels. Beijing and Hubei's slower recovery is consistent with later reopening and/or heavier restrictions. Early indications of patient flow is also positive, but it's too early to determine if it is pent-up demand due to the lockdown. We also heard today that China is lifting travel restrictions within China, which should facilitate business.
目前,由於 COVID-19 疫情造成的市場狀況仍在快速變動,我們不提供第二季指引,並撤回先前對 2020 全年的相關評論。我能提供的是以下方向性說明:就中國而言,中國是第一個受到 COVID-19 重大影響且在 1 月底幾乎一夕之間封鎖的主要國家;如同我們在 1 月財報電話會議中提供的第一季指引所反映,自 3 月上旬起已持續改善。我們在中國的病例收件量或訂單目前約為 1 月中旬水準的 80% 以上,但各省市之間每週波動仍相當明顯。請記住,病例收件與訂單到病例出貨之間約有 3 至 4 週的時間落差。中國各省復甦並不一致,但皆持續改善。廣東、上海與資陽目前已回到或高於疫情前水準。北京與湖北復甦較慢,與較晚重啟及/或較嚴格限制一致。病患回流的初步跡象亦為正向,但仍過早判斷是否為封鎖期間累積的遞延需求。我們今天也聽到中國正在解除中國境內的旅行限制,這應有助於業務推進。
APAC, excluding China, is still very fluid as Japan shut down later than the rest of APAC, and other countries like Taiwan and Korea are also improving, but are trailing China.
亞太地區(不含中國)仍然非常多變,因為日本的封鎖時間比亞太其他地區更晚;而台灣、韓國等其他國家也在改善,但仍落後於中國。
For the Americas, it's unclear how volume will evolve due to staggered lockdown and subsequent staggered reopenings by state. We would expect the situation in the U.S. to be similar to what we've seen in China, with recovery starting in the states in the middle of the country and working its way out to the coast on a city-by-city basis.
就美洲而言,由於各州採取錯峰封鎖、其後又錯峰重啟,量能將如何演變仍不明朗。我們預期美國的情況會與我們在中國看到的類似:復甦將從美國中部各州開始,並以逐城方式向沿海推進。
In LATAM, it is still fluid as it is shut -- it shut down later than the rest of the Americas. The EMEA market is beginning to open up, and Germany is making good strides. We are monitoring each market to see how each is responding to the various government isolation regulations and is still fluid and a lot of variability week-to-week.
在拉丁美洲(LATAM),情勢仍然多變,因為目前仍處於停擺——其封鎖時間也比美洲其他地區更晚。歐洲、中東與非洲(EMEA)市場正開始開放,德國也取得良好進展。我們正在監測各個市場,以了解其對各國政府不同隔離規定的反應;整體仍然多變,且每週之間的變異性很大。
For iTero, as a result of COVID-19, we did see some deferral purchase decisions at the end of the quarter, and I would expect that to continue.
就 iTero 而言,受 COVID-19 影響,我們確實在季度末看到部分採購決策延後,我預期這種情況將會持續。
We finished Q1 with $791 million in cash and cash equivalents. Since then, we have closed our purchase of exocad for $431 million on April 1. Align's priorities during the pandemic are to take care of our employees, customers and shareholders. With these priorities in mind, we are taking actions to ensure the business is well positioned to weather the pandemic.
我們在第一季結束時持有 7.91 億美元的現金及約當現金。此後,我們已於 4 月 1 日以 4.31 億美元完成對 exocad 的收購。疫情期間,Align 的優先事項是照顧我們的員工、客戶與股東。基於這些優先事項,我們正採取行動,以確保公司具備良好條件度過疫情。
In order to maintain our financial health, we are taking the following actions: holding our current headcount level steady to support the initiatives Joe discussed while making sure we are prepared for the market recovery; controlling discretionary spending such as travel and meeting-related expenses; slowing some of our capital expenditures and working with many vendors who have allowed us to increase payment terms while providing extended payment terms to many of our customers. As always, we are balancing future investments to drive growth in a vastly underpenetrated market versus making the appropriate cost reductions and cash actions that have less impact to the business.
為了維持財務健康,我們正採取以下行動:維持目前人力規模不變,以支持 Joe 所談到的各項計畫,同時確保我們已為市場復甦做好準備;控管差旅與會議相關費用等可自由裁量支出;放緩部分資本支出,並與許多供應商合作(他們允許我們延長付款期限),同時也為許多客戶提供延長付款條件。一如既往,我們在「於滲透率仍極低的市場中進行未來投資以推動成長」與「採取對業務影響較小的適當成本削減與現金措施」之間取得平衡。
With that, I'll turn it over to Joe for final comments. Joe?
接下來我把時間交給 Joe 做最後的評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John, and thanks again for joining us today.
謝謝你,John,也再次感謝各位今天加入我們。
Before I close, I want to take a minute to talk about some of Align's actions to support relief efforts in the communities in which we live and work. One of the things that makes Align a great place to work is the concern our employees have for the world around us and their commitment to helping others. The passion is core to our purpose of transforming smiles and changing lives. And in this time of need, how we support our employees and customers and serve our communities is more important than ever.
在我結束之前,我想花一點時間談談 Align 為支持我們生活與工作所在社區的救援工作所採取的一些行動。讓 Align 成為優秀工作場所的原因之一,是我們員工對周遭世界的關懷,以及他們致力於幫助他人的承諾。這份熱忱是我們「改變笑容、改變人生」使命的核心。而在這個需要幫助的時刻,我們如何支持員工與客戶、以及如何服務社區,比以往任何時候都更重要。
Early on in the outbreak, we donated RMB 1 million to the Chinese Red Cross to support relief efforts and what were then some of the hardest hit areas. More recently, we committed USD 1 million to the Align Foundation, Align's donor-advised fund through Fidelity Charitable. And our teams have been working together to source and supply additional personal protection equipment, or PPE, and medical supply donations for frontline health care workers in the communities we serve. Here's some slides to give you more details on this.
疫情爆發初期,我們向中國紅十字會捐贈人民幣 100 萬元,以支持救援工作以及當時受創最嚴重的一些地區。近期,我們承諾向 Align Foundation(Align 透過 Fidelity Charitable 設立的捐贈者建議基金)捐贈 100 萬美元。此外,我們的團隊也共同努力,採購並提供更多個人防護裝備(PPE)與醫療物資,捐贈給我們所服務社區的一線醫護人員。接下來的投影片會提供更多細節。
Finally, thanks to the ingenuity and diligence of our manufacturing engineering team, we're able to leverage our 3D printing technology and manufacturing expertise to produce face shields and medical swabs for COVID-19 testing kits. Through our network of connections with hospitals across the globe, we are donating them to hospitals with the most critical needs. As our existing 3D printing equipment is highly customized for aligner fabrication and can't be reconfigured, we acquired some new separate 3D printers to specifically help with relief efforts. I'm extremely proud of what our employees are doing individually to make a difference and what Align is doing as a business overall.
最後,憑藉我們製造工程團隊的創意與勤勉,我們得以運用 3D 列印技術與製造專業,生產防護面罩與 COVID-19 檢測套件所需的醫用採檢拭子。透過我們與全球各地醫院的聯繫網絡,我們將其捐贈給需求最迫切的醫院。由於我們現有的 3D 列印設備高度客製化、用於製作隱形牙套,無法重新配置,因此我們另外採購了一些新的獨立 3D 印表機,專門用於支援救援工作。我對員工個人所做的努力、以及 Align 作為企業整體所做的一切,感到非常自豪。
In summary, we're all operating in a tough environment. And even as we start to see signs of recovery in some geographies, we don't know when we'll get back to normal or even near-normal operations. As always, we're committed to the safety and well-being of our employees, doctor partners, their staff and patients. That remains our top priority in the weeks and months ahead. That and working with our stakeholders and communities to get through this together. With that said, I want to make it clear that we are not resting on our laurels waiting for the business in better days. Align Technology believes in playing offense and investing for our future. And that includes, first and foremost, protecting the jobs of our employees and keeping them ready to pivot for a fast recovery. That means no furloughs, no reduced salaries, staying focused on our long-term strategy. Employees remain our most strategic asset. Closing the exocad acquisition in early April to help expand our digital platform for the ortho-restorative treatment. We are very excited about this opportunity. Adding resources to support international expansion. For example, approximately 100 new sales reps in China. Improving virtual treatment options and releasing new products and digital tools to meet our customers' needs, like Invisalign Virtual Appointment and Invisalign Virtual Care to help doctors and patients connect while practices are closed and beyond.
總結來說,我們都在艱難的環境中運作。即使我們開始在某些地區看到復甦跡象,我們仍不知道何時能回到正常、甚至接近正常的營運狀態。一如既往,我們致力於員工、醫師合作夥伴、其團隊與病患的安全與福祉。這仍將是未來數週與數月的首要優先事項;同時也會與利害關係人及社區攜手共度難關。話雖如此,我想明確表示:我們不會躺在功勞簿上,等待景氣好轉。Align Technology 相信要主動出擊,為未來投資。其中首要之務,就是保障員工的工作,並讓大家隨時準備好在快速復甦時轉向應對。這意味著不實施無薪假、不降薪,並持續聚焦於我們的長期策略。員工仍是我們最具策略性的資產。我們在 4 月初完成 exocad 收購,以協助擴展我們在矯正與修復治療(ortho-restorative treatment)方面的數位平台;我們對此機會感到非常興奮。我們也增加資源以支持國際擴張,例如在中國新增約 100 名銷售代表。並改善虛擬治療選項,推出新產品與數位工具以滿足客戶需求,例如 Invisalign Virtual Appointment 與 Invisalign Virtual Care,協助診所在關閉期間及之後,讓醫師與病患保持連結。
Key to expanding our digital platform in a post-COVID-19 environment. Investing in marketing and media to reach our consumers while they're at home during the pandemic and keep our brand top of mind, something that other companies have stopped to conserve cash. Extending our working capital to help our customers manage their cash flow and expenses. We are very aware of the near-term volume challenges of consumer sheltering in place, closed ortho and dental offices and possible delays in new treatment as consumers go back to work and evaluate their priorities. But we're still focused on and investing in a vastly underpenetrated market and believe that Align is uniquely positioned for recovery and continued growth coming out of the pandemic. COVID-19 will continue to have significant implications to the world and to our industry. Our digital platform has made it possible for thousands of doctors and patients to continue Invisalign treatments throughout this global disruption, thanks to the digital orthodontics and Invisalign aligners, digital treatment planning and virtual monitoring and care. I think coming out of this, more doctors than ever will have experienced the benefit of digital treatment and digital tools for their practices and many who have seen firsthand the limitations and frustrations of the traditional analog approach to patient treatment, like wires and brackets.
這些都是在後 COVID-19 環境中擴展我們數位平台的關鍵。我們也投資行銷與媒體,在疫情期間消費者居家時觸及他們,並讓品牌保持在消費者心中——而其他公司為了保留現金已停止這類投入。我們延長營運資金支援,以協助客戶管理現金流與支出。我們非常清楚,短期內因消費者居家避疫、矯正與牙科診所關閉,以及消費者復工後重新評估優先順序,可能導致新療程延後,將對量能帶來挑戰。但我們仍聚焦並投資於一個滲透率仍極低的市場,並相信 Align 在疫情後的復甦與持續成長方面具備獨特優勢。COVID-19 將持續對世界與我們的產業帶來重大影響。我們的數位平台使數以千計的醫師與病患得以在這次全球性衝擊期間持續進行 Invisalign 療程,這要歸功於數位矯正與 Invisalign 隱形牙套、數位治療規劃,以及虛擬監測與照護。我認為在這之後,將有比以往更多的醫師體驗到數位治療與數位工具對診所的益處;也有許多人親身感受到傳統類比方式(例如鋼絲與托槽)在病患治療上的限制與挫折。
With that said, I want to thank you again for joining the call. I look forward to updating you on our progress as the year unfolds. Now I'll turn the call over to our operator for questions.
話說到這裡,再次感謝各位加入本次電話會議。我期待在今年接下來的時間裡,向各位更新我們的進展。現在我把電話交給接線員進行問答。
Operator
Operator
(Operator Instructions) Our first question comes from the line of Nathan Rich with Goldman Sachs.
(接線員指示)我們的第一個問題來自 Goldman Sachs 的 Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Appreciate all the color you gave on the call. I guess, Joe, maybe starting with China serving potentially as a guide for how the U.S. and EMEA might recover. Was there anything that you would call out in terms of either the types of cases or the channels that started to come back first, I guess, in China? And as we think about if China does serve as a guide for the U.S., does that sort of mean that we're looking at sort of like 3 to 4 months for kind of those case receipts to get back to that 80% level that you referenced in your remarks?
感謝你們在電話會議中提供的所有補充資訊。我想,Joe,或許先從中國談起,因為中國可能可作為美國與 EMEA 復甦的參考。在中國方面,你是否能指出有哪些病例類型或通路是最先回來的?另外,若中國確實可作為美國的參考,是否意味著我們大概需要 3 到 4 個月,才能讓你在談話中提到的病例收案回到約 80% 的水準?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I think first of all, China is China, right? China has very rigid lockdown procedures. They were into this first. I don't think you can really take a vector from China and just work it from the United States or from a Western geography in general. We also see, as John indicated in his written script, is that this is coming up in China by city. And we see Beijing and Wuhan area and all Hubei Province being behind in that sense. So I think as you look at the United States, too, New York and California will come up differently than the middle part of the nation is what we're seeing right now, too. So you talked about some segmentation in the sense of how it's come back in China, too, remember, it's primarily a comprehensive product base that we have in China. And it's pretty much stay. I mean we're selling some moderate there and some different things. But it's primarily coming back as a comprehensive piece. So again, I don't think that's a vector that we'll use when you look at other areas, too.
是的。我想首先,中國就是中國,對吧?中國的封鎖措施非常嚴格,而且他們最早面對這件事。我不認為你能從中國推導出一條趨勢向量,然後直接套用到美國或一般西方地區。我們也看到——如 John 在書面講稿中所指出——中國的復甦是以城市為單位逐步回升。而在這方面,北京、武漢地區以及整個湖北省相對落後。因此我認為,當你看美國時,紐約與加州的回升方式也會與全國中部不同,這也是我們目前看到的。你提到中國回升的某種分層情況;同時也要記得,我們在中國主要是以綜合型產品為主。我們也有銷售一些中度(moderate)以及其他不同產品,但主要回升的仍是綜合型產品。因此,再次強調,我不認為在看其他地區時,我們會把這當作可直接套用的向量。
So I mean there's no question, Nathan, the other countries will come back. I just am very reluctant to take a vector from China and really relate that to the Western economies in different countries because it's all being handled differently around the world.
所以我的意思是,毫無疑問,Nathan,其他國家會回來。我只是非常不願意用中國的軌跡作為向量,然後把它真正套用到不同國家的西方經濟體,因為全球各地的處理方式都不一樣。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Okay. Joe, appreciate that. I guess just a quick follow-up. I mean when you think about these practices kind of opening back up, and you made some comments about how you're supporting customers, are there any changes that you're thinking about from like a marketing or levers that you've kind of used in the past, maybe gearing those up as you think about helping volumes start to kind of get back to more normalized levels?
好的。Joe,感謝你的說明。我想再快速追問一下。當你想到這些診所逐步重新開放,而你也提到你們如何支援客戶時,從行銷或你們過去用過的一些槓桿來看,你們是否在考慮做任何改變?例如隨著你們認為量能開始回到較正常水準,是否會把那些槓桿再加大一些?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
And we honestly feel that, particularly in the orthodontic community, there'll be a much harder leaning toward a digital kind of environment because with the chance of reinfection rates with COVID-19 and concerns about future shutdowns or slowdowns, as we mentioned in our scripts, you just have a lot of variability and flexibility that you can use in a digital format that you can't use in an analog format. So we'll be going to our customers with programs that really help them through, to figure out how to convert more and more of their volume to a digital environment. Not that we haven't done that before, but we'll be very specific about it. And as we move into teen season, teen season second quarter, you'll see us really focused on teens because we know orthos will be focused on teens, too. And that's a different demographic. It segments differently in a sense of our product lines like First and math, and we'll also be ready with PPE equipment and other things. They'll prepare doctors for the concerns that they're going to have of protecting their patients and also their employees, too. Did I miss anything, John, or anything you'd add?
而我們坦白說覺得,特別是在齒顎矯正社群,會更大幅度地傾向數位化的環境,因為考量到 COVID-19 的再感染機率,以及對未來可能再度停工或放緩的擔憂——正如我們在講稿中提到的——你會面臨很多變動性;而在數位形式下,你能運用的變通性與彈性,是類比形式做不到的。所以我們會帶著一些方案去找客戶,真正協助他們度過這段期間,並協助他們思考如何把越來越多的量能轉到數位環境。不是說我們以前沒做過,但我們會更具體地去做。隨著我們進入青少年旺季——青少年旺季在第二季——你會看到我們非常聚焦在青少年,因為我們知道矯正醫師也會把重點放在青少年。而那是不同的人口族群;就我們的產品線而言,它在某種程度上會以不同方式做區隔,例如 First 和 math(等產品線)。此外,我們也會準備好 PPE 裝備和其他東西,協助醫師因應他們對於保護病患以及員工的疑慮。我有漏掉什麼嗎,John?或你有什麼要補充的?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Nope, that's good.
沒有,這樣很好。
Operator
Operator
Our next question comes from the line of Brandon Couillard with Jefferies.
我們的下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Joe or John, can you sort of just talk about the flexibility you have in your cost structure, how much of OpEx is discretionary or variable? It sounds like you're focused on kind of holding Align in terms of headcount and marketing. But how should we think just about the leverage you have to kind of control costs during this period right now?
Joe 或 John,你們能否談談你們在成本結構上的彈性?營運費用(OpEx)中有多少是可裁量或可變動的?聽起來你們的重點是在人力與行銷方面維持 Align 的配置。但在目前這段期間,我們應該如何看待你們用來控制成本的槓桿空間?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Brandon, this is John. Yes, as we said, there are levers that we could pull. Just as we accelerate growth, there's levers we pull. And when we look at our existing OpEx, as we look to spend some of our marketing dollars, where we spend it, how we spend it, there's levers around that spend. As with the travel restrictions and less conferences and so on, there's a lot of other operating expenditures that can be pushed out and not spend currently. So we're focused in on and still investing for the future, to be able to work with our doctors, as Joe has mentioned, on a lot of new technologies, and making sure that we keep the employees and the focus that we have on our structure that we have, but we'll modulate as we needed -- as we need to going forward if it's needed.
是的,Brandon,我是 John。是的,正如我們所說,我們有一些可以拉動的槓桿。就像我們加速成長時會拉動槓桿一樣。當我們檢視現有的營運費用(OpEx)時,包含我們要花多少行銷預算、花在哪裡、怎麼花,這些支出都有可調整的槓桿。再加上旅行限制、會議減少等等,還有很多其他營運支出可以延後、目前先不花。所以我們的重點是:一方面仍為未來投資,能夠與醫師合作——如 Joe 提到的——在許多新技術上持續推進;同時也確保我們保留員工,維持我們既有的組織結構與專注點。但如果未來有需要,我們也會視情況調整——在往前走的過程中按需調節。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
And then a follow-up for Joe. As you think about sort of the leverage you have to drive demand, would you expect to be somewhat more aggressive in terms of ASPs? And are you planning to adjust your Advantage program levels or hurdles to give dentists a bit of a break, given they've had their offices closed?
接著追問 Joe。當你思考你們用來拉動需求的槓桿時,你是否預期在 ASP(平均售價)方面會更積極一些?另外,你們是否計畫調整 Advantage 計畫的等級或門檻,讓牙醫在診所關閉之後能稍微喘口氣?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Brandon, we've already extended from an Advantage tier standpoint with our customers when they went into that. So I don't know how much of an effect that will have on an ASP standpoint because we basically will be holding them to where they are. But overall, it's not price. It's our strategy here as we come up out of here. It's how do we support our customers in a digital environment. We're trying to explain how do we really support them from a PPE standpoint and an export standpoint. We talked about loans, different things from a cash flow standpoint. We know many of them are going to be challenged in that way. And we have been offering some payables relief and deferral going forward. So it's a broad aspect of needs, we think, our customers will have. Advantage is just one part of that, but it's what we can bring to these customers holistically to help their practice and help them grow.
Brandon,我們已經就 Advantage 等級的角度,對客戶做了延長,當他們進入那個狀態時就已經延長了。所以我不確定這對 ASP 會有多大影響,因為我們基本上會讓他們維持在原本的等級。整體而言,重點不是價格。當我們走出這段期間時,我們的策略是:如何在數位環境中支援客戶。我們也在嘗試說明如何從 PPE 以及出口(export)等面向真正支援他們。我們談到貸款、以及從現金流角度的不同作法。我們知道很多人會在這方面面臨挑戰。我們也一直在提供一些應付帳款(payables)的紓困與延後付款安排。所以我們認為客戶會有廣泛的需求。Advantage 只是其中一部分;更重要的是我們能以整體方式為這些客戶帶來什麼,來幫助他們的診所並協助他們成長。
Operator
Operator
Our next question comes from the line of Jon Block with Stifel.
我們的下一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Joe, you mentioned protecting employees, no furloughs or salary cuts. I'm just curious about the competition. And has anything changed in the marketplace around the competitive landscape? We've heard some chatter about sort of, call it, cut back in the orthodontic divisions of some of the other players, but maybe you can elaborate on what you're hearing or seeing out there.
Joe,你提到保護員工、不實施無薪假或減薪。我想了解一下競爭對手的情況。市場上競爭態勢有任何改變嗎?我們聽到一些傳聞,說其他一些業者的齒顎矯正部門有縮編之類的情況,但也許你可以多談談你聽到或看到的狀況。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Hey Jon, I don't want to be specific, but I mean, most of our competitors have had layoffs or cutbacks in some way. We've been -- just been blessed with a really strong balance sheet going in. This allows us to have the flexibility and do it, as we do. We're a growth business. You know that, Jon, well. We're set out for 20% to 30% kind of growth, and we have to position ourselves for that. In that sense, making sure that our production capacity is ready, that our employee base is ready, too. Our sales teams are really critical in that sense, too. And it's wonderful. We can see some of the investments like Invisalign Virtual Assistance and things that we're working with, with customers right now, that we can launch those products and continue to drive those products going forward with a full force engineering team also.
嗨 Jon,我不想講得太具體,但我的意思是,我們大多數競爭對手都以某種方式進行裁員或縮減。我們在進入這段期間時——很幸運——資產負債表非常強健。這讓我們有彈性,能像現在這樣做。我們是一家成長型企業。你很清楚,Jon。我們的目標是 20% 到 30% 左右的成長,因此我們必須為此做好配置。就這點而言,要確保我們的產能準備就緒,也要確保員工基礎準備就緒。我們的銷售團隊在這方面也非常關鍵。而且很棒的是,我們可以看到一些投資,例如 Invisalign Virtual Assistance 以及我們目前正與客戶合作的事項;我們能推出這些產品,並在未來持續推動這些產品,同時也有完整戰力的工程團隊支援。
So from a competitive standpoint, I mean, we're seeing varying degrees of cutbacks and moves in that sense. But we're not focused on that, Jon, really. We're just focused on what we think we should do, what's important in our portfolio and how we can help our doctors out.
所以從競爭角度來看,我們確實看到不同程度的縮減與動作。但 Jon,我們其實不把焦點放在那上面。我們只專注在我們認為該做什麼、我們產品組合中什麼最重要,以及我們如何幫助醫師。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Helpful. The second one's a little bit long. But just on [Swift]. I know you kicked off a pilot recently. I think it's an important sort of initiative long term to better get after the lower acuity market. I'm just curious, Joe, you kicked it off when there was a lot going on, so did you get enough of a signal during that time to share some takeaways from the Swift initiative? And then could we see you lean on that a little bit more in coming months? Because it is a little bit more price-sensitive for the consumer. It has a monthly and in this environment of job uncertainty might really resonate. So curious your thoughts there.
好的,很有幫助。第二個問題有點長,但關於 [Swift]。我知道你們最近啟動了一個試點。我認為這是一個長期來看很重要的計畫,有助於更好地切入低複雜度市場。我想問的是,Joe,你們在事情很多的時候啟動了它,所以在那段期間你們是否獲得足夠的訊號,可以分享一些 Swift 計畫的心得?另外,接下來幾個月你們會不會更倚重它一些?因為它對消費者來說價格敏感度更高,而且是月付制;在這種工作不確定的環境下可能會很有共鳴。所以想聽聽你的看法。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Jon, when we launched [Swift], the timing couldn't be worse in that sense, because COVID hit pretty far after that, but we got a pretty strong signal in that, that we think we understand at least parts of the demand equation. We're going to look at rolling that out in a broader sense going forward in the United States and maybe in different parts of the world.
是的,Jon,當我們推出 [Swift] 時,就那個意義上來說時機再糟也不過,因為 COVID 在那之後不久就嚴重爆發;但我們確實收到相當強的訊號,讓我們認為至少對需求方程式的某些部分已有所理解。我們會評估在美國、以及可能在世界不同地區,以更廣泛的方式逐步推廣。
But I think when you talked about the price point on ASP and different things, and obviously, we broached that with the doctors who are part of the Swift program. But Jon, you know this, I want to make sure our callers understand. This is -- our margins on this product line are accretive to our gross margin area and how we're going into it. So it's real important in how we position that going forward. But again, those 300 million patients out there, we know there's some price sensitivity and then there's some clinical aspects from a simplicity standpoint that we're going at with that product line. And we think it will respond real well in a broader sense as we begin to roll that out.
但我想,當你談到 ASP 的價格點以及其他不同因素時——而且很明顯地,我們也已經和參與 Swift 計畫的醫師討論過這些——但 Jon,你也知道,我想確保我們的聽眾理解:這條產品線的毛利率,對我們的整體毛利率是具增益(accretive)的,這也關係到我們如何切入。因此,我們未來如何定位它非常重要。不過再說一次,外面有 3 億名患者,我們知道其中存在一定的價格敏感度;同時也有一些從簡單性角度出發的臨床面向,是我們用這條產品線要去切入的。我們認為,當我們開始更廣泛地推廣時,它會在更大範圍內有很好的反應。
Operator
Operator
Our next question comes from the line of Steve Beuchaw with Wolfe Research.
下一個問題來自 Wolfe Research 的 Steve Beuchaw。
Stephen Christopher Beuchaw - Director of Equity Research
Stephen Christopher Beuchaw - Director of Equity Research
I also wanted to ask in a way about [Swift], but with a very different angle. As we think about the operating environment prospectively for some amount of time, people are going to be concerned about safety. And so I wonder to what extent, and you definitely alluded to this in your prepared remarks, can you flex some of the technology that you have with Swift and some of the things you have in development to decrease the amount of face-to-face contact? Again, I know you alluded to this, but I wonder if you could take it a few steps further, give us more context, a little bit more insight into your plans. How do you think about making Invisalign treatment achievable with a minimum of in-person interaction for those who might be concerned about that, even in an environment where PPE is more widely used?
我也想用一種方式問一下關於 [Swift] 的問題,但角度非常不同。當我們前瞻性地思考未來一段時間的營運環境時,人們會擔心安全性。因此我想知道,在多大程度上——而且你在事先準備的發言中確實提到過——你能否運用你們在 Swift 上擁有的一些技術,以及你們正在開發中的一些功能,來降低面對面接觸的程度?我知道你提到過,但我想請你再往前多談幾步,給我們更多背景與對你們計畫更深入的一些洞見。你們如何看待讓 Invisalign 治療在盡量減少親自互動的情況下仍可實現,以回應那些可能對此感到擔憂的人?即便是在 PPE 更廣泛使用的環境中也是如此。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, that's top of mind as we do things today, too. So actually, even before COVID, when we designed Swift, Swift was designed for basically 2- to 3-doctor direct contacts. And that's it. And that was part of making the equation for doctors a profitable equation, too. Then you roll in our remote monitoring capability that we just rolled out, which gives doctors a tool to be able to do that, and we'll be able to enhance that tool going forward.
Steve,這也是我們今天在做事情時最優先考量的重點。其實在 COVID 之前,當我們設計 Swift 時,Swift 的設計目標基本上就是 2 到 3 次醫師的直接接觸,就這樣而已。這也是讓醫師端的經濟模型成為一個可獲利方程式的一部分。接著再加上我們剛推出的遠端監測能力,這讓醫師有工具可以做到這件事,而且我們未來也能持續強化這個工具。
There's limited amount of attachments in IPR on things like [Swift], too. And it's not that our clinical protocols are going to, in some way, decrease in the sense of what the clinical capability are and what we can do. We're also cognizant in the sense of time and mouth. And we'll adjust that. We might time those things differently to help doctors, too. But there's a lot of different things that we're contemplating. We talked about at the conference last year about direct printed attachments and those kinds of things that in the future and not-too-distant future will allow a lot less contact and a lot of speed from a productivity standpoint with doctors and patients, be able to do those things.
像 [Swift] 這類方案在附件(attachments)與 IPR 的需求也相對有限。這並不是說我們的臨床流程會在某種程度上降低——就臨床能力與我們能做的事情而言不會縮水。我們也意識到時間與口內操作的考量,並會做出調整。我們可能會以不同的時點安排這些事項來協助醫師。但我們正在思考很多不同的做法。我們去年在會議上談到過直接列印附件(direct printed attachments)等這類技術;在未來、而且是不太遙遠的未來,這將能大幅降低接觸,並從醫師與病患的生產力角度帶來更高速度,讓他們能完成這些事情。
So it's the right line of questioning, Steve. So remote monitoring, a digital platform that allows us to anticipate exactly when you'll be seeing a patient and what will need to be done in that sense, not duplicating treatments at the office that don't need to be done and keeping up with patients in a sense remotely and only calling them in when something goes awry or a doctor has a concern in some way. So we feel our digital platform and things we have in the pipeline, Steve, are really well positioned to address that.
所以這個提問方向很正確,Steve。遠端監測、以及一個數位平台,能讓我們預先判斷你究竟何時需要見到病患,以及在那個情境下需要做哪些事——避免在診所做不必要、重複的處置;同時以遠端方式持續追蹤病患,只有在出現偏差或醫師在某方面有疑慮時才把病患叫回來。因此我們認為,我們的數位平台以及研發管線中的項目,Steve,確實非常有利於因應這些需求。
Stephen Christopher Beuchaw - Director of Equity Research
Stephen Christopher Beuchaw - Director of Equity Research
Okay. Good. Good to hear. The second question I wanted to ask actually relates to the practice in the U.S. So it's been -- well, for some of us months, but for -- in practices, certainly many weeks. How do you think about the most likely -- as you talk to the orthodontic and dental societies, the most likely path forward for practice reopening in the U.S.? And I know it's a complicated question because there will be a lot of regional variation and staging, but to what extent -- to any extent you can, can you give us your sense for how you guys are thinking about that and your planning specific to the U.S.?
好的。很好。很高興聽到。第二個問題其實與美國的診所端有關。這已經——對我們其中一些人來說是好幾個月,但對診所而言至少也已經好幾週了。當你們與矯正與牙科學會交流時,你們如何看待美國診所重新開放最可能的路徑?我知道這是個複雜的問題,因為會有很多區域差異與分階段推進,但在你能分享的範圍內——你能否談談你們對此的看法,以及你們在美國的具體規劃?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Steve, I think it's going to be -- it's certainly not going to be uniform in the sense of how we go about that. Whether it's in the states or anywhere around the world, there are going to be certain government restrictions. I think there's going to be certain -- when I say restrictions, too, it's going to be equipment that's available from a PPE standpoint, what patients are going to be prepared to do? We see some -- you look at treatment planning alternatives or when patients enter an office right now, they're not even coming into the office at times. They stay in their car until they're summoned in some way, to make sure that there's less interaction and proper social distancing within the office itself. So I can't really tell yet.
是的,Steve,我認為這在推進方式上肯定不會一致。不論是在各州或全球任何地方,都會有一些政府限制。我所說的限制也包括:從 PPE 的角度來看可取得的設備有哪些、病患願意配合到什麼程度?我們看到一些——你看治療規劃的替代方案,或是病患現在進入診所時的流程,有時甚至不會立刻進到診所裡。他們會待在車上,直到以某種方式被叫進去,以確保互動更少,並在診所內維持適當的社交距離。所以我現在還真的無法判斷。
The only thing is, I think there's going to be a lot more caution about, obviously, transmission of the disease. That's going to include how you stage patients, how often you see these patients. And I think from a dental versus orthodontic standpoint, there are obviously going to be different protocols because of the different procedures that take place there.
唯一可以確定的是,我認為大家會對疾病傳播更加謹慎。這會包括你如何分流安排病患、你多久見一次這些病患。我也認為,從牙科與矯正的角度來看,因為所進行的處置不同,顯然會有不同的流程規範。
Steve, there's an interesting article in the New York Times yesterday that really did an X/Y, kind of a graph on different types of professions that interface with customers and which ones are -- most time from an intimacy standpoint and could transmit a virus. And dentistry came up almost on the top of that whole thing. So I mean that's going to be watched closely, and I think we have to make sure we work with our customers -- I mean doctors and to help them through this, too.
Steve,《紐約時報》昨天有一篇有趣的文章,做了一個 X/Y 的分析——有點像圖表——比較不同類型、需要與客戶互動的職業,哪些在「親密接觸」的時間上最長、因此可能傳播病毒。牙科幾乎排在最前面。所以這件事一定會被密切關注,我認為我們必須確保與我們的客戶——也就是醫師——合作,並協助他們度過這段期間。
Operator
Operator
Our next question comes from the line of Elizabeth Anderson with Evercore ISI.
下一個問題來自 Evercore ISI 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
I wanted to ask a question on the sort of digital actions, sort of what you guys can do in the near term. I know you said that you were sort of unveiling the app as sort of like a beta test, and you were rapidly rolling that forward and allowing more access and training and things to that. Can you speak to any more of the details in terms of sort of like the uptake or how the training is going or the case use of that for like ongoing patients?
我想問一個關於數位化行動的問題,也就是你們短期內能做些什麼。我知道你說你們把這個 app 以類似 beta 測試的方式推出,並且快速推進,讓更多人能使用並提供訓練等。你能否再多談一些細節,例如目前的採用情況、訓練進展如何,或是對於既有病患的持續追蹤,這個工具的案例使用情況?
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Liz, just to make clear, you're talking about Virtual Appointment and Virtual Care, right?
Liz,我先確認一下,你指的是 Virtual Appointment 和 Virtual Care,對嗎?
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Yes. Yes.
是的。是的。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Or Elizabeth, you're talking about just training of doctors online rather than face-to-face?
或者 Elizabeth,你是指醫師的線上訓練,而不是面對面的訓練?
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Oh, no. Sorry. I meant on the Virtual Care side.
喔不是,抱歉。我是指 Virtual Care 那一端。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Okay. And so your question is on the workflow of that? Is that...
好的。所以你的問題是關於它的工作流程?是這個意思嗎……
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Yes. Just sort of the way (inaudible) and sort of like how have you seen the uptake of that so far? Is it -- I assume that there's some sort of training that has happened beforehand or how have you been able to roll that out, considering that there should have been beta testing right before you -- this all happened.
是的。就是(聽不清)以及你們目前看到的採用情況如何?它是——我想應該事前有做一些訓練,或者你們是如何把它推出去的?考量到在這一切發生之前,你們應該才剛要進行 beta 測試。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I get it, Elizabeth. Look, first of all, we've been -- we didn't just roll it -- we just rolled this out. We've been working on it for over a year. And so we actually rushed this to the market. And as we rushed it to the market, we were cautious in a sense of how many doctors we -- you had in the program. And we started here in the United States, and now we're gradually moving it to broader, to more doctors in the U.S. and across the world, too. We had to train the doctors to do this, but the great thing is it is on our IDS platform. And it has a great user interface that the team put together. So from the feedback that I've gotten from the teams and the doctors, too, that user interface has been pretty simple in how they've been able to put that piece together. And remember, the whole idea there is just that how do you stay in these kind of lockdown periods or future workflows where patients don't want to come into the office all the time to see a doctor, how in the world can you track treatment and how can you communicate? And it's gone really well. And we will have actually more doctors who want it, that we can give it to right now. We just want to make sure we don't burden them, and we just roll it out piece by piece to make sure that it's robust enough to handle more and more doctors over time.
我明白了,Elizabeth。你看,首先,我們並不是才開始做——我們只是最近才把它推出。我們已經投入研發超過一年了。所以我們其實是加速把它推向市場。而在加速推出時,我們在納入多少醫師參與計畫這件事上也相對謹慎。我們先從美國開始,現在也逐步擴大到更廣泛的範圍,讓美國以及全球更多醫師加入。我們確實需要訓練醫師如何使用,但很棒的是它是在我們的 IDS 平台上運作,而且團隊打造了很好的使用者介面。因此從我從團隊與醫師那裡得到的回饋來看,這個介面相當簡單,讓他們能把這一塊串起來。請記得,整個概念就是:在這種封鎖期間,或未來病患不想一直到診所見醫師的工作流程下,你要如何追蹤治療進度、如何溝通?目前進展非常順利。而且實際上,想要使用的醫師比我們現在能立刻提供的還多。我們只是想確保不要造成他們負擔,因此會分階段逐步推出,確保系統足夠穩健,能隨時間承載越來越多醫師。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Okay. Perfect. And so just on (inaudible), you did a virtual visit with some of the (inaudible) either support the next set of (inaudible) for a patient.
好的。完美。所以就(聽不清楚)而言,你和部分(聽不清楚)做了一次虛擬訪視,用來支援下一組(聽不清楚)給某位病患。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. More than 2,000 doctors. We have more than 2,000 doctors trained right now -- trained and beginning to use Virtual Care. And obviously, we have tens of thousands of doctors out there that will want to roll this out, too, and we think they'll have an interest in it.
是的。超過 2,000 位醫師。我們目前已有超過 2,000 位醫師受訓——已受訓並開始使用虛擬照護(Virtual Care)。而且很明顯地,外面還有數以萬計的醫師也會想要推行這個,我們認為他們也會對此有興趣。
And we've had over -- just -- I'm getting some other data here, too. We have over 3,500 appointments right now that have been done through Virtual Care. Elizabeth, if we just think about this, too, it just makes sense, right? I mean and everybody's kind of -- in today's COVID environment, it obviously makes sense to try to eliminate patients trying to have this person-to-person contact. But I mean going forward, too, in a digital kind of environment, having these kind of tools just make sense from a productivity standpoint, for both doctors and patients, too. So we'll continue to invest pretty heavily in this, to get better and better at it. This is our initial launch, but you'll see more and more iterations to help to enhance this platform.
而且我們已經有超過——就是——我這邊也在取得一些其他數據。我們目前已經有超過 3,500 次門診預約是透過虛擬照護完成的。Elizabeth,如果我們也一起想想這件事,其實很合理,對吧?我的意思是,在今天這種 COVID 的環境下,顯然嘗試減少病患進行這種人與人接觸是合理的。但我的意思是,往後在一個更數位化的環境中,擁有這類工具,從生產力角度來看,對醫師與病患也都很合理。所以我們會持續在這方面投入相當多資源,讓它做得越來越好。這是我們的初始上線,但你會看到越來越多的迭代,來協助強化這個平台。
Operator
Operator
Our next question comes from the line of Jeff Johnson with Baird.
我們的下一個問題來自 Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Just 2 questions, I guess. One, we've seen some news in the last couple of days from one of your DTC competitors on some patents they were able to get and some Better Business Bureau recommendations on some advertising. I would love your view, not so much on what that means for them, but does that have any implications for you, either on the [Swift] product where some of that is kind of a monthly fee? I don't think any of that would trip any of the stuff in their new patent. But also if they have to rein in a little bit of their advertising. I would assume that's a good thing for you, but would just like to get your view.
我想就兩個問題。第一,過去幾天我們看到你們某個 DTC 競爭對手的新聞,提到他們取得了一些專利,以及更佳商業局(Better Business Bureau)對某些廣告的建議。我想聽聽你的看法,不是那對他們意味著什麼,而是這對你們是否有任何影響——不論是在 [Swift] 產品上(其中有些是按月收費)?我不認為那會觸發他們新專利中的任何內容。但另外,如果他們必須稍微收斂一些廣告投放,我猜這對你們是好事,但還是想聽聽你的看法。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jeff, overall, that's not a model that competes with us. We go directly to doctors in everything we do, work through a doctor base. And so from what we know of the -- I haven't looked at the patent or whatever. I just read most of the information that's out there. That has to do with Invisalign. And we have to do with just scanning a patient in a store and transferring a file that never really reaches a doctor in any way except from a teledentistry standpoint. So we don't see it being an issue for us at all.
Jeff,整體而言,那不是一個會與我們競爭的模式。我們在所有事情上都是直接面向醫師,透過醫師基礎來運作。所以就我們所知——我沒有去看那個專利或其他內容。我只是讀了外面大部分的資訊。那主要是跟 Invisalign 有關。而我們這邊是把病患在門市做掃描,並傳輸一個檔案,而這個檔案除了從遠距牙科(teledentistry)的角度外,基本上不會以任何方式真正到達醫師那裡。所以我們完全不認為這會對我們造成問題。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Sorry, I was on mute. And then just my follow-up question. Obviously, we're all going to be watching PPE. We're all going to be watching patients' willingness to go into these offices. What are you hearing from the doctor side? From an orthodontist standpoint, the office is maybe a little cleaner, less aerosolization, if that's even a word, of fluids and what have you. So are your orthodontists, especially kind of chomping at the bit to get back? I'm sure they are financially. But do they feel safe? Do they feel like this will be an environment they can bring their staff back into, it can bring patients into, things like that?
抱歉,我剛剛靜音了。那我的追問是:很明顯地,我們都會關注 PPE。我們也都會關注病患是否願意走進這些診所。你從醫師端聽到的是什麼?從矯正醫師的角度來看,診所可能更乾淨、較少產生氣溶膠(如果這算一個詞的話)——也就是體液之類的噴散。所以你們的矯正醫師是否特別迫不及待想回去?我確定他們在財務上是。但他們覺得安全嗎?他們覺得這會是一個可以讓員工回來、也能讓病患進來的環境嗎?諸如此類。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
From an orthodontist standpoint, Jeff, you're right to segment those 2 because, obviously, dentistry is a lot different than orthodontist and whatever. The orthodontists that we look to, I would say that they're not concerned, but they're cautious, in the sense of what they have to do, the precautions they have to make with the patients and also with their employees internally. They are anxious to get back. But I mean there's a good degree of caution to make sure that they come back in the right way, in a thoughtful way, too. And again, I think this could vary by state also, in the sense of how it's applied and what kind of regulations are put in place. But I know there's -- they're really interested to come back. And the ones that really went into this was a significant amount of Invisalign. Feel good that they've been able to stay in contact with their patients and be able to send packs of aligners with different things that's helped in any kind of course correction or holding patients to where they are.
從矯正醫師的角度來看,Jeff,你把這兩者區分開來是對的,因為很明顯地,牙科和矯正科差異很大等等。我們所接觸的矯正醫師,我會說他們不是擔心,但很謹慎,因為他們必須做的事情、對病患以及對內部員工所需採取的防護措施。他們很想回去。但同時也有相當程度的謹慎,確保以正確的方式、也以更周全的方式回到工作崗位。而且我想這也會因州而異,取決於如何落實以及會有哪些法規到位。但我知道——他們真的很有興趣回來。那些在這段期間大量使用 Invisalign 的診所,感覺很好,因為他們能夠持續與病患保持聯繫,也能寄送一包包的牙套以及其他東西,協助進行任何療程修正或讓病患維持在目前的進度。
So on the dentistry side, I mean, that's obviously going to be different. But when you think about it, Invisalign's one of the least invasive procedures that you're going to see in dentistry. And we'll certainly be emphasizing that and trying to work with doctors to help them through.
所以在一般牙科端,我的意思是,那顯然會不一樣。但你想想看,Invisalign 是你在牙科領域會看到的侵入性最低的療程之一。我們當然會強調這一點,並嘗試與醫師合作,協助他們度過這段期間。
And we talked about iGo and the growth of iGo, and that's a great -- when you think about, you think, we talk about a digital platform, that's a terrific product for GPs in the sense of being able to leverage that and then send the more difficult cases to the orthodontist side. We'll be working with GPs to really help through that transition.
我們也談到 iGo 以及 iGo 的成長;那是一個很棒的——當你想到、我們談到數位平台時,對一般牙醫(GP)而言那是個很出色的產品,因為他們可以善用它,然後把更困難的病例轉介到矯正端。我們會與一般牙醫合作,真正協助他們完成這個轉換。
Operator
Operator
Our next question comes from the line of John Kreger with William Blair.
我們的下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Joe, could you remind us what's the lag time between order receipt from a customer -- from when -- to the point where you can actually ship the aligners?
Joe,你能提醒我們一下,從收到客戶的訂單——從那個時間點——到你們實際能出貨牙套之間的時間落差是多少?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
So we call it CCA, and CCA would be in order. And I'd say, John can correct me on this, I'd say it's 4 days to 5 days.
所以我們稱之為 CCA,而 CCA 會是在下單之後。我想,John 可以糾正我,我會說大概是 4 天到 5 天。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
But from an order to an after shipment, it could be 3 to 4 weeks, because it's the back and forth. He's describing kind of initial to the actual shipment. It could be 3 to 4 weeks depending on how much back and forth. As you know, John, getting that treatment plan just exactly the way the doctor has and wants it takes a number of iterations. And then the actual manufacture and shipment can do. So on the outset, it could be 4 weeks in total.
但從下單到出貨之後,可能會是 3 到 4 週,因為中間有來回往返。他描述的是從一開始到實際出貨。依來回溝通的程度不同,可能是 3 到 4 週。如你所知,John,要把治療計畫調整到完全符合醫師的想法與需求,需要多次迭代。然後才是實際製造與出貨。所以一開始算起來,總共可能是 4 週。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Okay. Great. So from a fabrication standpoint, for a region like the U.S. that got locked down in mid-March, that backlog probably would have -- would it be reasonable to assume that kind of carried through to mid-April?
好的。很棒。所以從製造的角度來看,像美國這樣在 3 月中旬封鎖的地區,那個積壓量大概會——假設合理的話——會延續到 4 月中旬嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Well, there's still going to be back and forth that goes on. So I mean you have patients that have not been able to make it into the office, to look at the final plan for doctors to meet, other things that go on. So it's going to vary by this until the doctor actually approves the treatment plan and then it gets manufactured.
嗯,仍然會有來回往返的流程。所以我的意思是,你有一些病患無法進診所,去看最終方案、讓醫師面談核對,還有其他事情。因此在醫師實際核准治療計畫、然後進入製造之前,這會因情況而異。
So remember, our business is a made-to-order business. I mean there's no inventory. And as things change in the environment, when there's -- people can't come to the office to seek treatment or to make sure that they're going to approve that treatment plan, things shut down right away. And it takes some time to see that ramp back up.
所以請記得,我們的業務是按單生產(made-to-order)的業務。也就是說,沒有庫存。當環境變化、當——人們無法到診所尋求治療,或無法確認他們會核准那個治療計畫時,業務會立刻停下來。而要看到它再度爬升回來,需要一些時間。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. That's helpful. And then anything you can give us in terms of contribution from exocad since that'll be in there for the full second quarter?
很好。這很有幫助。那關於 exocad,由於第二季會完整納入,你們能否提供一些它的貢獻度資訊?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Nothing on that, John, that we're giving on any forward guidance, other than what we've had in our prepared remarks.
是的。John,關於那部分我們不會提供任何前瞻指引,除了我們在事先準備的講稿中已經提到的內容之外。
Operator
Operator
Our next question comes from the line of Kevin Caliendo with UBS.
我們的下一個問題來自 UBS 的 Kevin Caliendo。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
First question. You're talking about a digital and analog world. But if I think about Align a year from now, and hopefully, we're through this, competitively, not just with other manufacturers, but against wires and brackets, I mean, is there a marketing pitch here that the orthodontist can go and say, hey, instead of using wires and brackets, or you can even pitch to the orthodontist, that there might be a greater demand to use clear aligners versus wires and brackets simply because you're able to keep patients out of the -- keep them out of the orthodontist office or the dentist office more frequently? Is that something that you've contemplated that could necessarily be a positive for market share for you?
第一個問題。你們在談數位與類比的世界。但如果我想像一年後的 Align——希望那時我們已經度過這一切——在競爭上,不只是和其他製造商競爭,也包括和鋼絲與托槽競爭。我的意思是,這裡是否有一個行銷訴求,讓矯正醫師可以去說:嘿,相較於使用鋼絲與托槽——或者你甚至可以對矯正醫師推廣——可能會有更高的需求去使用透明牙套而不是鋼絲與托槽,單純因為你能讓病患更少進到——讓他們更少頻繁地進到矯正診所或牙科診所?你們是否有考慮過這件事,可能會對你們的市占率帶來正面效果?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Kevin, prior to the COVID-19, we have a program called ADAPT where doctors -- orthodontists come to us and say, look, we want to go primarily 80%, 90% Invisalign. How do we do that, right? And so how do you do that, you're going to crank up your volume in a significant way. And to do that, you just need to drive more productivity. And so we were pushing that piece, is you don't have to see patients as often, right? You might have patients come back every 3 or 4 weeks to adjust wires and brackets. Likely, they're going to come back, they're doing their episode with a wire that comes out, and it's an emergency procedure, about 20% of an ortho's time, that does a lot of wires and brackets or emergency cases. We talk to doctors about how you can really control your schedule much better in a digital environment and how patients don't have to come back so often. We'd talk about 7 weeks, 8 weeks of seeing patients. Now that becomes even more magnified when you think about possibility of infection and concern about COVID-19. It's not just a productivity play. It's a way of being able to treat patients in a way that's safer for your staff and safer for those patients, too. So we'll certainly be emphasizing that. And -- but it goes -- it just goes along with a digital platform. It is -- it's much more productive. And doctors will need less time per patient. And I mean we've known that well from the millions of patients that we've done.
Kevin,在 COVID-19 之前,我們有一個名為 ADAPT 的計畫,醫師——矯正醫師——會來找我們說:你看,我們希望主要做到 80%、90% 的 Invisalign。要怎麼做到,對吧?那要怎麼做到呢?你就得大幅拉高你的病例量。要做到這點,你只需要提升更多生產力。因此我們一直在推動的是:你不必那麼頻繁地看診,對吧?你可能會讓病患每 3 或 4 週回診一次去調整鋼絲和托槽。很可能他們回診是因為療程中鋼絲脫落,這屬於緊急處置;對於大量做鋼絲與托槽或急診病例的矯正醫師而言,這大約占了 20% 的時間。我們會和醫師討論,在數位化環境下你如何能更好地掌控你的排程,以及病患不需要那麼常回診。我們會談到 7 週、8 週才看一次病患。當你考量到感染的可能性以及對 COVID-19 的擔憂時,這一點就更加被放大。這不只是提升生產力的作法;這也是一種能以更安全的方式治療病患的方法,對你的員工更安全,對病患也更安全。所以我們當然會強調這點。而且——但這也——這就是數位平台的一部分。它——它的生產力高得多。醫師每位病患所需的時間會更少。我的意思是,從我們已治療的數百萬名病患中,我們早就很清楚這一點。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
One quick follow-up. The DSO spiked. I know you made some comments earlier about offering payment terms and loans and the like. Does that explain the bump up to 9 day? You said expect DSOs to continue to move higher? Sort of what was the impact of, I guess, would be improved payment terms for the doctors on your DSOs?
再快速追問一下。DSO(應收帳款週轉天數)飆升了。我知道你先前提到提供付款條件、貸款之類的安排。這是否解釋了上升到 9 天的原因?你說預期 DSO 會持續走高?我想問的是,改善醫師付款條件對你們的 DSO 造成了什麼影響?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, it varies by doctors. And (inaudible) as they have working capital concerns, we're in a fortunate position to be able to help. So we work with them to kind of manage their cash flow in terms of paying us. And then the DSO impact is obviously impacted by lower revenue as well, which causes that to increase. So -- but we're working closely with our customers and making sure that they can help weather the storm, stay close with them. And as they start to ramp up, we want to be their partners with them, and cash is an important part of that.
是的,會因醫師而異。而且(聽不清)當他們有營運資金方面的顧慮時,我們很幸運能夠提供協助。所以我們會與他們合作,從支付給我們的角度來協助管理他們的現金流。然後 DSO 的影響顯然也會受到營收下降的影響,這會使其上升。所以——但我們正與客戶密切合作,確保他們能夠度過難關,並與他們保持緊密聯繫。當他們開始逐步恢復時,我們希望成為他們的合作夥伴,而現金是其中很重要的一部分。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Operator, we'll take one more question, please.
接線員,請再讓我們接一個問題。
Operator
Operator
Our final question comes from the line of Richard Newitter with SVB Leerink.
我們最後一個問題來自 SVB Leerink 的 Richard Newitter。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
This is Jaime on for Rich this afternoon. I just -- a housekeeping one. You guys had said in the beginning of your prepared remarks, incremental impact from COVID-19 was about 50 fewer cases and, I think, $85 million less revenue. So I just wanted to make sure that, that is something -- like the way that we should be thinking about that is incremental to what you had originally contemplated in your 1Q guidance of, I think, about a 20,000 to 25,000 case impact and a $30 million to $35 million revenue impact?
我是今天下午代 Rich 提問的 Jaime。我只是——一個釐清性問題。你們在一開始的事先準備發言中提到,COVID-19 的增量影響大約是少了 50 個病例,並且我想是少了 8,500 萬美元的營收。所以我想確認一下,我們應該如何理解這件事——也就是說,這是相對於你們原先在第一季財測中所預期的增量影響嗎?我記得你們當時提到大約 20,000 到 25,000 個病例的影響,以及 3,000 萬到 3,500 萬美元的營收影響?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
That's correct, Jaime. You would think of that as incremental to how we guided.
沒錯,Jaime。你可以把它視為相對於我們指引的增量影響。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
Got it. So the fair way to think about then in total would be about $115 million to $120 million of impact to revenue from the coronavirus in the first quarter?
了解。那麼公平的理解方式是,合計起來第一季因冠狀病毒對營收的影響大約是 1.15 億到 1.2 億美元?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
That's correct.
沒錯。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
Got it. Okay. And just last one for me. Any sort of update on where you guys stand with launching the palate expander product?
了解。好。那我最後一個問題:你們在推出腭擴弓器(palate expander)產品方面,目前進度有沒有任何更新?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Hi Jaime, I'll take that. We're still -- we have the design. We're still working that piece. We have to find an effective way to manufacture it. So I don't have a date that I can give you, but I can tell you that it's high on our priority list.
嗨 Jaime,我來回答。我們仍然——已經有設計了。我們還在推進那一塊。我們必須找到一個有效的製造方式。所以我沒有辦法給你一個日期,但我可以告訴你,這在我們的優先事項清單上排名很高。
Operator
Operator
Thank you. We have reached the end of our question-and-answer session. I'd like to turn the call back over to Ms. Stacy Shirley for any closing remarks.
謝謝。我們的問答環節到此結束。接下來我想把電話交回給 Stacy Shirley 女士,請她做結語。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, thank you, everyone, for joining us. We look forward to speaking with you at upcoming virtual financial conferences in the future. If you have any questions, please contact Investor Relations, and hope you have a great day. Take care.
好的,謝謝各位今天加入我們。我們期待未來在即將舉行的線上財務會議上與各位交流。如果你有任何問題,請聯絡投資人關係部門,也希望你今天愉快。保重。
Operator
Operator
Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation. Have a wonderful day.
謝謝。今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。祝您有美好的一天。